Luminex (LMNX) 10-K 26 Feb 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 24, 2014	Jun. 30, 2013
Entity [Abstract]	'	'	'
Entity Registrant Name	'Luminex Corp	'	'
Entity Central Index Key	'0001033905	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	41,975,783	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$769,750,174

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS(USD ($))	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$67,924	$42,789
Short-term investments	4,517	13,607
Accounts receivable (net of allowance for doubtful accounts of $4,579 and $444 at December 31, 2013 and 2012, respectively)	30,948	33,273
Inventories, net	30,487	29,937
Deferred income taxes	7,265	4,783
Prepaids and other	5,229	4,388
Total current assets	146,370	128,777
Property and equipment, net	32,793	26,229
Intangible assets, net	60,295	65,218
Deferred income taxes	11,913	14,360
Long-term investments	0	3,000
Goodwill	50,738	51,128
Other	3,937	8,463
Total assets	306,046	297,175
Current liabilities:	'	'
Accounts payable	10,698	9,650
Accrued liabilities	11,624	12,866
Deferred revenue	4,980	4,134
Current portion of long-term debt	1,194	1,138
Total current liabilities	28,496	27,788
Long-term debt	463	1,702
Deferred revenue	2,482	2,933
Other	4,985	5,085
Total liabilities	36,426	37,508
Stockholders' equity:	'	'
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,133,653 shares at December 31, 2013; 40,824,932 shares at December 31, 2012	41	41
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	296,931	293,392
Beginning balance, December 31, 2012	419	1,101
Accumulated deficit	-27,771	-34,867
Total stockholders' equity	269,620	259,667
Total liabilities and stockholders' equity	$306,046	$297,175

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Allowance for doubtful accounts	$4,579	$444
Stockholders' equity:	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	41,133,653	40,824,932
Common stock, outstanding (in shares)	41,133,653	40,824,932
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]	'	'	'
Revenue	$213,423	$202,582	$184,339
Cost of revenue	69,797	60,008	58,849
Gross profit	143,626	142,574	125,490
Operating expenses:	'	'	'
Research and development	45,041	42,989	35,391
Selling, general and administrative	87,301	72,626	62,881
Amortization of acquired intangible assets	4,099	4,243	3,375
Restructuring Charges	2,418	0	0
Total operating expenses	138,859	119,858	101,647
Income from operations	4,767	22,716	23,843
Interest expense from long-term debt	-76	-198	-308
Other income, net	6,733	262	394
Income before income taxes	11,424	22,780	23,929
Income taxes	-4,328	-10,373	-9,455
Net income	7,096	12,407	14,474
Other Comprehensive Income	'	'	'
Foreign currency translation adjustments	-681	144	-79
Unrealized losses on available-for-sale securities, net of tax	-1	-27	-87
Other comprehensive (loss) income	-682	117	-166
Comprehensive income	$6,414	$12,524	$14,308
Net income per share, basic (in dollars per share)	$0.17	$0.30	$0.35
Shares used in computing net income per share, basic (in shares)	40,799	40,927	41,262
Net income per share, diluted (in dollars per share)	$0.17	$0.30	$0.34
Shares used in computing net income per share, diluted (in shares)	41,986	41,884	42,537

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income	$7,096	$12,407	$14,474
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	15,922	14,364	11,887
Stock-based compensation	9,221	9,915	11,417
Deferred income tax benefit (expense)	551	2,699	-592
Excess income tax benefit from employee stock-based awards	-2,569	-6,457	-7,614
Gain on sale of assets	-5,173	0	0
Non-cash restructuring charges	4,137	0	0
Other	-1,209	1,157	232
Changes in operating assets and liabilities:	'	'	'
Accounts receivable, net	2,346	-10,267	-899
Inventories, net	-3,005	-5,346	4,783
Other assets	-1,470	-617	-1,279
Accounts payable	962	3,286	-2,680
Accrued liabilities	-324	3,463	9,324
Deferred revenue	417	-321	-763
Net cash provided by operating activities	26,902	24,283	38,290
Cash flows from investing activities:	'	'	'
Purchases of available-for-sale securities	-10,005	-14,987	-47,743
Sales and maturities of available-for-sale securities	22,128	47,117	33,753
Purchase of property and equipment	-18,088	-9,767	-9,554
Business acquisition consideration, net of cash acquired	0	-48,199	-33,914
Purchase of cost method investment	0	-1,000	-2,000
Proceeds from sale of assets and investments	9,598	0	0
Acquired technology rights	-930	-1,592	-1,857
Net cash provided by (used in) investing activities	2,703	-28,428	-61,315
Cash flows from financing activities:	'	'	'
Payments on debt	-1,105	-1,025	-885
Proceeds from issuance of common stock	8,677	4,022	3,543
Payments for stock repurchases	-14,556	-20,916	-18,340
Excess income tax benefit from employee stock-based awards	2,569	6,457	7,614
Net cash used in financing activities	-4,415	-11,462	-8,068
Effect of foreign currency exchange rate on cash	-55	114	-112
Change in cash and cash equivalents	25,135	-15,493	-31,205
Cash and cash equivalents, beginning of year	42,789	58,282	89,487
Cash and cash equivalents, end of year	$67,924	$42,789	$58,282

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2010	$234,865	$41	$295,422	$1,150	($61,748)
Balance (in shares) at Dec. 31, 2010	'	41,245,033	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options (in shares)	'	304,125	'	'	'
Exercise of stock options	3,544	1	3,543	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)	'	312,101	'	'	'
Issuances of restricted stock, net of shares withheld for taxes	-2,486	0	-2,486	0	0
Stock compensation	11,417	0	11,417	0	0
Repurchase and retirement of common stock (in shares)	'	-892,302	'	'	'
Repurchase and retirement of common stock	-18,341	-1	-18,340	0	0
Net income	14,474	0	0	0	14,474
Tax benefits associated with options	7,548	0	7,548	0	0
Foreign currency translation adjustments	-79	0	0	-79	0
Other	-87	0	0	-87	0
Balance at Dec. 31, 2011	250,855	41	297,104	984	-47,274
Balance (in shares) at Dec. 31, 2011	'	40,968,957	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options (in shares)	'	486,766	'	'	'
Exercise of stock options	3,517	1	3,516	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)	'	340,216	'	'	'
Issuances of restricted stock, net of shares withheld for taxes	-3,189	0	-3,189	0	0
Stock compensation	9,915	0	9,915	0	0
Repurchase and retirement of common stock (in shares)	'	-1,006,303	'	'	'
Repurchase and retirement of common stock	-20,916	-1	-20,915	0	0
Issuance of common shares under ESPP (in shares)	'	35,296	'	'	'
Issuance of common shares under ESPP	504	0	504	0	0
Net income	12,407	0	0	0	12,407
Tax benefits associated with options	6,457	0	6,457	0	0
Foreign currency translation adjustments	144	0	0	144	0
Other	-27	0	0	-27	0
Balance at Dec. 31, 2012	259,667	41	293,392	1,101	-34,867
Balance (in shares) at Dec. 31, 2012	40,824,932	40,824,932	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options (in shares)	'	834,581	'	'	'
Exercise of stock options	7,562	1	7,561	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)	'	264,555	'	'	'
Issuances of restricted stock, net of shares withheld for taxes	-2,352	0	-2,352	0	0
Stock compensation	9,214	0	9,214	0	0
Repurchase and retirement of common stock (in shares)	'	-852,483	'	'	'
Repurchase and retirement of common stock	-14,556	-1	-14,555	0	0
Issuance of common shares under ESPP (in shares)	'	71,226	'	'	'
Issuance of common shares under ESPP	1,102	0	1,102	0	0
Net income	7,096	0	0	0	7,096
Tax benefits associated with options	2,569	0	2,569	0	0
Foreign currency translation adjustments	-681	0	0	-681	0
Other (in shares)	'	-9,158	'	'	'
Other	-1	0	0	-1	0
Balance at Dec. 31, 2013	$269,620	$41	$296,931	$419	($27,771)
Balance (in shares) at Dec. 31, 2013	41,133,653	41,133,653	'	'	'

DESCRIPTION_OF_BUSINESS_AND_SU

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1 - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Description of Business
	Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries.  The Company’s xMAP technology, an open architecture, multiplexing technology, allows the Luminex systems to simultaneously perform up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, LEDs, digital signal processors and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. The Company’s xMAP technology is currently being used within various segments of the life sciences industry which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research.  In addition to the Company's xMAP technology, its other offerings include its proprietary MultiCode technology, used for real-time PCR and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.
	The acquisition of GenturaDx was completed on July 11, 2012; therefore the results of operations of GenturaDx in the Company’s consolidated financial statements only include GenturaDx’s results since that date. The acquisition of LMA was completed on June 27, 2011; therefore the results of operations of LMA in the Company’s consolidated financial statements only include LMA's results since that date.
	The Company reclassified certain 2012 amounts in the accompanying consolidated financial statements to conform to the 2013 presentation. These reclassifications include $2.1 million and $2.0 million of ARP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment research and development expenses for the year ended December 31, 2012 and 2011, respectively. Additionally, $12.7 million and $12.4 million of TSP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment selling, general and administrative expenses for the year ended December 31, 2012 and 2011, respectively. These reclassifications had no effect on the Company's consolidated comprehensive income or stockholders' equity.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.
	Investments
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.  Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings.  Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates fair value of these investments.   Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity.  Marketable securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date.  The fair value of all securities is determined by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value.  Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
	Fair Value of Financial Instruments
	The fair values of financial instruments are determined by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, cost-method investments, long-term investments, accounts payable, accrued liabilities, and long-term debt.  Except for the fair value of the Company’s long-term debt, the fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2013 and 2012. See Note 7 for further details concerning fair value measurements and Note 14 for further details concerning the fair value of the Company’s long-term debt.
	Supplemental Cash Flow Statement Information (in thousands)
		Year Ended December 31,
		2013			2012			2011
	Cash paid during the period for taxes	$	1,284		$	761		$	1,520
	Cash paid during the period for interest and penalties	124			171			176
	Effect of acquisitions:
	Fair value of tangible assets acquired	—			1,682			6,048
	Liabilities assumed	—			(1,954		)	(164		)
	Cost in excess of fair value of assets acquired	—			8,292			532
	Acquired identifiable intangible assets	—			—			19,681
	Deferred tax assets (liabilities), net	—			2,526			7,617
	In-process research and development	—			40,100			286
		—			50,646			34,000
	Less accrued contingent consideration	—			1,370			—
	Less cash and cash equivalents acquired	—			1,077			86
	Net cash paid for business acquisition	$	—		$	48,199		$	33,914
	Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company’s short-term investments consist of investments in high credit quality financial institutions, non-government sponsored debt securities and corporate issuers.
	The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses and does not require collateral.
	Thermo Fisher Scientific, Inc., including One Lambda, Inc. acquired in 2012, accounted for 27%, 28% and 33% of the Company’s total TSP segment revenues in 2013, 2012 and 2011, respectively. Bio-Rad Laboratories, Inc. accounted for 15%, 14% and 14% of the Company’s total TSP segment revenues in 2013, 2012 and 2011, respectively.  EMD Millipore accounted for 11%, 13% and 11% of the Company's total TSP segment revenues in 2013, 2012, and 2011, respectively.  LabCorp, including acquired Genzyme Genetics, accounted for 44%, 45%, and 31% of the Company's total ARP segment revenues in 2013, 2012 and 2011, respectively.  Thermo Fisher Scientific, Inc. accounted for 0%, 18% and 24% of the Company’s total ARP segment revenues in 2013, 2012 and 2011, respectively.  Abbott Laboratories accounted for 2%, 9% and 10% of the Company’s total ARP segment revenues in 2013, 2012 and 2011, respectively.  No other customer accounted for more than 10% of total segment revenues in 2013, 2012 or 2011.
	Inventories
	Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company's markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company's policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company's assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company's estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be overvalued, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company's operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.
	Property and Equipment
	Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment.  The Company classifies the carrying value of Luminex xMAP Instruments placed within the reagent rental program and the instruments on loan to customers in property and equipment as "Assets on loan/rental."
	Goodwill and Other Intangible Assets
	Goodwill represents the excess of the cost over the fair value of the assets of the acquired business.  In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, on a reporting unit level.  All of the Company's goodwill relates to one reporting unit, our ARP segment, for goodwill impairment testing.  The Company has historically estimated the fair value of our ARP segment reporting unit using a discounted cash flow (DCF) analysis (“step one” analysis) of the Company’s projected future results.  The step one analysis performed by management in the fourth quarter of 2010 indicated the fair value the ARP segment reporting unit was significantly higher than the carrying value. In 2012 and 2011, the Company applies the accounting guidance which allows an entity to first assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount (“step zero” analysis). In performing the impairment test in the fourth quarter of 2013, the Company used the "step one" analysis. This analysis requires a comparison of the carrying value of the reporting unit to the estimated fair value of the reporting unit.  Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions. The Company's annual test did not result in an impairment charge in 2013 as the estimated fair value of the ARP segment reporting unit continues to exceed the carrying value by a significant enough amount that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit as determined under our "step one" analysis. No goodwill impairments were recorded in 2013, 2012 or 2011.
	The Company utilizes the income approach based on a DCF analysis to determine fair value estimates, and then uses market comparisons as a reasonability check to ensure that neither the income approach nor the market comparisons yielded significantly different results. The income approach calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value using a risk-adjusted discount rate.  The Company's estimates are based on revenue projections by product line, and include judgment based on historical growth and scheduled product approvals by the various governmental authorities.  The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The most significant assumptions used in the DCF methodology are the discount rate, based upon the estimated weighted average cost of capital (WACC), and the terminal growth rate, based upon strategic studies the Company commissioned and the Company's internal analysis.  The Company used the following rates in 2013:
	Assumptions		2013
	WACC		15	%
	Terminal Growth Rate		2.9	%
	To determine the Company's WACC rate, management performed a peer company analysis and considered the weighted average return on debt and equity, the updated risk-free interest rate, beta, equity risk premium, and entity specific size risk premium.  The Company's analysis yielded an estimated fair value in excess of the carrying value by over 25% for 2013.
	Concurrent with the above analysis, management performed a sensitivity analysis based upon reasonably likely changes to determine if the DCF analysis would result in impairment if the following changes were made to management's assumptions:  i) assumed the fair value of the reporting unit was lower by 10% or ii) future revenue was 75% of the Company's projections in the DCF model.  Neither of these sensitivity analyses resulted in an estimated fair value less than the carrying amount of the reporting unit.
	Intangible assets are amortized on a straight line basis over their respective estimated useful lives ranging from 5 to 15 years. As a result of the acquisition of GenturaDx in July 2012, the Company acquired in process research and development of $40.1 million.  In-process research and development will be an indefinite-lived intangible asset until completion or abandonment at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.
	Impairment of Long-Lived Assets
	Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.
	Revenue Recognition and Allowance for Doubtful Accounts
	Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company's systems.  The Company recognizes product revenue at the time the product is shipped provided there is persuasive evidence of an agreement, no right of return exists, the fee is fixed or determinable and collectability is probable.  There is no customer right of return in the Company’s sales agreements.  If the criteria for revenue recognition are not met at the time of shipment, the revenue is deferred until all criteria are met.
	The Company regularly enters into arrangements for system sales that are multiple-element arrangements, including services such as installation and training, and multiple products.   These products or services are primarily delivered within a short time frame, approximately three to six months, of the agreement execution date and can also be performed by one of the Company’s third-party partners.  Based on the terms and conditions of the sale, management believes that these services can be accounted for separately from the delivered system as the delivered products have value to customers on a stand-alone basis.  Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis.   Accordingly, the estimated selling price of services or products not yet performed or delivered at the time of system shipment are deferred and recognized as revenue as such services are performed.  The Company has typically been able to determine the selling price of each deliverable in a multiple-element arrangement based on the price for such deliverable when it is sold separately.  If vendor specific objective evidence (VSOE) is not determinable and when third-party evidence is not available, management uses the estimated selling price of a deliverable which is determined based upon the Company’s pricing policies, expected margin of the deliverable, geographical location and information gathered from customer negotiations.
	Within the diagnostic portion of the ARP segment, the Company provides systems and certain other hardware to customers through reagent rental agreements under which the customers commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for diagnostic assays and other disposables. Revenue is recognized over the defined contract term as assays and other disposable products are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred.
	Revenue from extended service agreements is deferred and recognized ratably over the term of the agreement.  The Company may also be entitled to milestone payments that are contingent upon achieving a predefined objective. The Company follows the milestone method of recognizing revenue from milestones and milestone payments are recorded as revenue in full upon achievement of the milestone. Revenues from royalties related to agreements with strategic partners are recognized when such amounts are reported to the Company; therefore, the underlying end user sales may be related to prior periods.
	Additional revenue is derived from cost-type contracts with the U.S. government. Revenue and profit under cost-plus service contracts is recognized as costs are incurred plus negotiated fees. Fixed fees on cost-plus service contracts are recognized ratably over the contract performance period as services are performed. Contract costs include labor and related employee benefits, subcontracting costs and other direct costs, as well as allocations of allowable indirect costs. For contract change orders, claims or similar items, judgment is required for estimating the amounts, assessing the potential for realization, and determining whether realization is probable. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known. Reimbursements of certain costs, including certain hardware costs or out-of-pocket expenses are included in revenue with corresponding costs included in cost of revenue as costs are incurred.
	The Company continuously monitors collections and payments from its customers and maintains allowances for doubtful accounts based upon its historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the Company’s expectations, there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment, in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.
	Product-Related Expenses
	The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.  Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred.  The Company does not have any direct-response advertising.   Advertising expenses, which include trade shows and conventions, were approximately $2.6 million, $2.4 million and $3.1 million for 2013, 2012 and 2011, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Operations.
	Research and Development Costs
	Research and development costs are generally expensed in the period incurred.  Nonrefundable advance payments for research and development activities for materials, equipment, facilities, and purchased intangible assets that have an alternative future use are deferred and capitalized.  The capitalized amounts are expensed as the related goods are delivered or the services are performed.  In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses.  These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from 1 to 2 years.
	Foreign Currency Translation
	The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters”. The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.
Incentive Compensation
Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes
The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.
The Company recognizes excess tax benefits associated with share-based compensation to stockholders’ equity only when realized. When assessing whether excess tax benefits relating to share-based compensation have been realized, the Company follows the with-and-without approach excluding any indirect effects of the excess tax deductions. Under this approach, excess tax benefits related to share-based compensation are not deemed to be realized until after the utilization of all other tax benefits available to the Company.
The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes” which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.
Earnings Per Share
Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.
Stock-Based Compensation
The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718).  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
Segment Reporting
Management has determined that the Company has two segments for financial reporting purposes:  the TSP segment and the ARP segment.  See Note 19 – Segment and Geographic Information.

RESTRUCTURING_Notes

RESTRUCTURING (Notes)	12 Months Ended
	Dec. 31, 2013
RESTRUCTURING [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
	NOTE 2 — RESTRUCTURING
	In August 2013, the Company announced a restructuring plan focused on its ARP segment's Newborn Screening Group and its Brisbane, Australia office where automated punching systems are designed and manufactured. The Company is exploring strategic alternatives for its Newborn Screening assets and related automated punching group, including a potential sale or abandonment of that business. The Company has reviewed the requirements for held-for-sale and discontinued operations presentation and has determined that this business did not qualify for this presentation at December 31, 2013. The Company will continue selling its automated punching systems while it explores strategic alternatives for this business.
	The Company recorded total pre-tax restructuring charges of $5.0 million in 2013, which primarily consisted of the non-cash estimated impairment of inventory, intangible assets, property and equipment, together with employee separation costs. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits. As a result of the organizational change, the Company eliminated approximately 5% of its workforce. In conjunction with the restructuring plan, the Company evaluated its tangible and intangible assets for estimated impairment and recorded non-cash impairment charges of $4.1 million in 2013. The Company determined the fair value of the assets based upon prices for similar assets.  See Note 9 — Goodwill and Other Intangible Assets.
	The Company will continue to review the remaining asset balances for possible further impairment until sale or abandonment. The Company will measure and accrue the facilities exit costs at fair value upon the Company's exit. Facilities exit costs will primarily consist of cease-use losses to be recorded upon vacating the facilities and fixed asset impairment.
	Statement of Comprehensive Income	2013 Restructuring Plan
	Non-cash impairment charges:
	Inventory	$	2,326
	Property and equipment	1,110
	Intangible Assets	700
	Employee separation costs	783
	Facility exit costs	—
	Other	50
	Total charges	$	4,969
	Recorded to cost of revenue	2,551
	Recorded to restructuring costs	$	2,418
	Rollforward of Accrued Restructuring
	Total charges	$	4,969
	Non-cash impairment charges	(4,136		)
	Employee separation payments	(655		)
	Facility exit costs	—
	Foreign exchange and other adjustments	(50		)
	Balance at December 31, 2013	$	128
	The remaining restructuring accrual balance is expected to be paid within the next six months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of December 31, 2013.

BUSINESS_COMBINATIONS

BUSINESS COMBINATIONS	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
BUSINESS COMBINATIONS	'
	NOTE 3 – BUSINESS COMBINATIONS
	2012 Acquisition
	On July 11, 2012, the Company completed its acquisition of GenturaDx, Inc., a British Virgin Islands corporation with operations in Hayward, California (“GenturaDx”). GenturaDx was a molecular diagnostics company in late stage development of a fully integrated, highly automated, real-time polymerase chain reaction (PCR) system that employs a single-use cassette for sample-to-answer workflow. Under the terms of the acquisition agreement, the Company acquired all of the outstanding capital stock of GenturaDx in exchange for approximately $49.3 million cash consideration, subject to working capital adjustments, plus (i) $3.0 million in consideration contingent upon achieving certain future development and regulatory milestones by December 31, 2013, (ii) up to $7.0 million in consideration contingent upon achieving certain future development and regulatory milestones by June 30, 2014 and (iii) additional consideration contingent upon acquired products exceeding certain revenue thresholds in each of 2013, 2014 and 2015.  Pursuant to ASC 805 "Business Combinations", the Company recorded an estimate of the fair value of the contingent consideration liability based upon future revenue estimates and weighted probability assumptions of development and regulatory outcomes. The discount rate is used in the estimate of fair value and was based on the weighted-average cost of capital of the acquired business plus a risk premium for a non-performance risk related to the liability. This analysis resulted in an initial contingent consideration liability of approximately $1.4 million, which was adjusted periodically as a component of other income, net based on changes in the fair value of the liability resulting from changes in the assumptions pertaining to the achievement of the defined milestones and revenue thresholds. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820 "Fair Value Measurements and Disclosures". This fair value measurement is directly impacted by the Company's estimate of future incremental revenue of the business. Accordingly, if actual revenue is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or benefits, respectively, as appropriate. See Note 7 for further discussion of the Company's contingent consideration.
	Of the approximately $8.1 million related to the GenturaDx acquisition that was deposited in escrow as security for potential indemnity claims and certain other expressly enumerated matters, approximately $5.0 million remains in escrow as of December 31, 2013. Additionally, up to 30% of the remaining milestone payments are subject to certain set-off rights of the Company for indemnification claims under the acquisition agreement. The Company's acquisition of GenturaDx was funded with cash on hand.
	The results of operations for GenturaDx have been included in the Company’s consolidated financial statements from the date of acquisition as part of the Company’s ARP segment.
	The purchase price consideration is as follows (in thousands):
	Cash	$	49,276
	Contingent consideration	1,370
	Total purchase price	$	50,646
	The acquisition of GenturaDx has been accounted for as a business combination in accordance with ASC 805 and, as such, the assets acquired and liabilities assumed have been recorded at their respective fair values. The determination of fair value for the identifiable tangible and intangible assets acquired and liabilities assumed requires extensive use of estimates and assumptions. Significant estimates and assumptions include, but are not limited to estimating future cash flows and determining the appropriate discount rate. The following table summarizes the estimated fair values of GenturaDx’s assets acquired and liabilities assumed at the acquisition date (in thousands):
	Net tangible liabilities assumed as of July 11, 2012	$	(272	)
	Intangible assets subject to amortization	40,100
	Deferred tax assets, net	2,526
	Goodwill	8,292
	Total purchase price	$	50,646
	The $40.1 million of intangible assets subject to amortization have been identified as in-process research and development (IPR&D) that had not yet reached technological feasibility as of the acquisition date. Technological feasibility is primarily established by obtaining regulatory approval to perform certain diagnostic testing on the Company's systems. The IPR&D project relates to GenturaDx's diagnostic testing prototype system designed to run sample-to-answer cassettes in clinical settings and the related cassette design. This project is expected to be completed in 2014. The fair value of the IPR&D has been estimated using the multi-period excess earnings method, a form of the income approach and cash flow projections were discounted using a rate of 29.5%, which reflects the risk associated with the intangible asset related to the other assets and the overall business operations of the Company.
	The excess of the purchase price over the fair value of the tangible net assets, liabilities and intangible assets acquired was recorded to goodwill. The goodwill recognized is mainly attributable to the compatibility between the Company's MultiCode-RTx chemistry and the prototype system and the expectation that the system together with the Company's MultiCode-RTx chemistry will allow the Company to leverage years of previous assay development and make custom assay development accessible to a greater number of diagnostic labs, even those with little molecular diagnostics experience.
	Acquisition related costs of $4.3 million have been included in selling, general and administrative costs for 2012.  GenturaDx had no revenue and operating loss of $7.9 million from the date of acquisition to December 31, 2012, including the impact of the acquisition costs.  In the fourth quarter of 2012, the Company ceased using the Hayward, California facility, whose operating lease commitment was acquired under the GenturaDx acquisition in July 2012. The Company has accrued a liability based upon the estimated fair value of the costs that will continue to be incurred under the lease, including an estimate of sublease rental income.
	Unaudited Pro Forma Financial Information
	GenturaDx’s results of operations have been included in the Company’s financial statements since the date of the acquisition. The unaudited pro forma financial information set forth below assumes that GenturaDx had been acquired at the beginning of each of the 2012 and 2011 fiscal years, and includes removal of interest expense on GenturaDx’s debt extinguished at the date of acquisition, removal of acquisition costs and the impact of purchase accounting adjustments, and tax adjustments. This unaudited pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have resulted had the acquisition been in effect at the beginning of the periods presented. In addition, the unaudited pro forma financial information is not intended to be a projection of future results and does not reflect any operating efficiencies or cost savings that might be achievable.
		Year Ended December 31,
		2012			2011
		(unaudited, in thousands except per share data)
	Revenue	$	202,582		$	184,339
	Income from operations	16,276			10,224
	Net income	9,118			5,194
	Net income per common share, basic	$	0.22		$	0.13
	Shares used in computing net income per common share, basic	40,927			41,262
	Net income per common share, diluted	$	0.22		$	0.12
	Shares used in computing net income per common share, diluted	41,884			42,537
	2011 Acquisition
	On June 27, 2011, the Company completed its acquisition of EraGen Biosciences, Inc., a Delaware corporation, now referred to as Luminex Madison (LMA), a privately-held molecular diagnostic company in Madison, Wisconsin, which was founded in 1999, for the aggregate cash purchase price of $34.0 million.  This acquisition was undertaken to provide the Company access to a portfolio of molecular diagnostic assays based on a proprietary technology called MultiCode.  LMA is an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications.
	The results of operations for LMA have been included in the Company’s consolidated financial statements from the date of acquisition as part of the Company’s ARP segment.  All of the purchase price deposited in escrow as security for breaches of representations and warranties and certain other expressly enumerated matters and to satisfy any post-closing adjustments has been released to LMA's former shareholders and certain other individuals as of December 31, 2013.
	The acquisition of LMA has been accounted for as a business combination in accordance with ASC 805 Business Combinations and, as such, the assets acquired and liabilities assumed have been recorded at their respective fair values. The determination of fair value for the identifiable tangible and intangible assets acquired and liabilities assumed requires extensive use of estimates and assumptions. Significant estimates and assumptions include, but are not limited to estimating future cash flows and determining the appropriate discount rate.  The following table summarizes the estimated fair values of LMA’s assets acquired and liabilities assumed at the acquisition date (in thousands):
	Net tangible assets assumed as of June 27, 2011	$	5,884
	Intangible assets subject to amortization	19,967
	Deferred tax assets, net	7,617
	Goodwill	532
	Total purchase price	$	34,000
	Acquisition related costs of $2.1 million were included in selling, general and administrative costs for 2011.  Acquired finished goods and work-in-process inventory was valued at its estimated selling price less the sum of costs of sales efforts and a reasonable profit allowance for the Company's selling effort and, with respect to work-in-process inventory, estimated costs to complete. This resulted in a fair value adjustment that increased finished goods inventory by approximately $3.3 million. As the Company sold the acquired inventory in 2011, its costs of sales reflected the increased valuation of the inventory, which reduced the Company's gross margins in 2011.  LMA had revenue of $7.6 million and operating loss of $4.6 million from the date of acquisition to December 31, 2011, including the impact of the acquisition costs and the fair value adjustment to inventory above.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
INVESTMENTS	'
	NOTE 4 – INVESTMENTS
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income (Loss)		Losses in Accumulated Other Comprehensive Income (Loss)		Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—	$	46,422
	Non-government sponsored debt securities	4,517		—		—		4,517
	Total current securities	50,939		—		—		50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,939	$	—	$	—	$	50,939
	Available-for-sale securities consisted of the following as of December 31, 2012 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income (Loss)		Losses in Accumulated Other Comprehensive Income (Loss)		Estimated Fair Value
	Current:
	Money Market funds	$	16,987	$	—	$	—	$	16,987
	Non-government sponsored debt securities	13,602		5		—		13,607
	Total current securities	30,589		5		—		30,594
	Noncurrent:
	Non-government sponsored debt securities	3,000		—		—		3,000
	Total noncurrent securities	3,000		—		—		3,000
	Total available-for-sale securities	$	33,589	$	5	$	—	$	33,594
	There were $0 and $6.0 million in proceeds from the sales of available-for-sale securities during the years ended December 31, 2013 and 2012, respectively.  Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. Net unrealized holding gains and losses on available-for-sale securities are included in accumulated other comprehensive gain (loss) as of December 31, 2013. All of the Company's available-for-sale securities with gross unrealized losses as of December 31, 2013 and 2012 had been in a loss position for less than 12 months.
	The estimated fair value of available-for-sale debt securities at December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
	Due in one year or less	$	4,517
	Due after one year through two years	—
		$	4,517
	Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

ACCOUNTS_RECEIVABLE_AND_RESERV

ACCOUNTS RECEIVABLE AND RESERVES	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
ACCOUNTS RECEIVABLE AND RESERVES	'
	NOTE 5 - ACCOUNTS RECEIVABLE AND RESERVES
	The Company records an allowance for doubtful accounts based upon a specific review of all outstanding invoices, known collection issues and historical experience. The Company regularly evaluates the collectability of its trade accounts receivables and performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and its assessment of the customer’s current creditworthiness. These estimates are based on specific facts and circumstances of particular orders, analysis of credit memo data and other known factors.  Accounts receivable consisted of the following at December 31 (in thousands):
		2013			2012
	Accounts receivable	$	35,527		$	33,717
	Less: Allowance for doubtful accounts	(4,579		)	(444		)
		$	30,948		$	33,273
	The following table summarizes the changes in the allowance for doubtful accounts (in thousands):
	Balance at December 31, 2010	$	298
	Recoveries charged to costs and expenses	(168		)
	Write-offs of uncollectible accounts	(13		)
	Balance at December 31, 2011	$	117
	Increases charged to costs and expenses	335
	Write-offs of uncollectible accounts	(8		)
	Balance at December 31, 2012	$	444
	Increases charged to costs and expenses	4,604
	Write-offs of uncollectible accounts	(469		)
	Balance at December 31, 2013	$	4,579

INVENTORY_NET

INVENTORY, NET	12 Months Ended
	Dec. 31, 2013
Inventory, Net [Abstract]	'
INVENTORY, NET	'
	NOTE 6 - INVENTORIES, NET
	Inventories consisted of the following at December 31 (in thousands):
		2013		2012
	Parts and supplies	$	19,002	$	18,259
	Work-in-progress	4,747		4,831
	Finished goods	6,738		6,847
		$	30,487	$	29,937
	The Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $12.1 million at December 31, 2013. Should production requirements fall below the level of the Company’s commitments, the Company could be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 7 – FAIR VALUE MEASUREMENT
	ASC 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:
	Level 1—Quoted prices in active markets for identical assets or liabilities.
	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value.  There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2013.
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 (in thousands):
		Fair Value Measurements at December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	46,422		$	—	$	—	$	46,422
	Non-government sponsored debt securities	—			4,517		—		4,517
	Liabilities:
	Contingent consideration	—			—		—		—
		Fair Value Measurements at December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	16,987		$	—	$	—	$	16,987
	Non-government sponsored debt securities	—			16,607		—		16,607
	Liabilities:
	Contingent consideration	—			—		1,370		1,370
	The Company records contingent consideration resulting from a business combination at its fair value on the acquisition date. The Company determines the fair value of the contingent consideration based primarily on the timing and probability of success of clinical events or regulatory approvals, the timing and probability of success of meeting commercial milestones, such as sales levels of a specific product, and discount rates. The Company's contingent consideration liability arose in connection with the GenturaDx acquisition. The Company re-evaluates its assumptions for its contingent consideration fair value determinations each quarter. Changes to the fair value of contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in estimates of the likelihood of or timing of achieving any development or commercial milestones, changes in the probability of certain clinical events or changes in the assumed probability associated with regulatory approval. As a result of changes in assumptions surrounding the probability of success of meeting the timing of commercial milestones contemplated in the GenturaDx acquisition agreement, the Company adjusted the contingent consideration liability related to the GenturaDx acquisition from $1.4 million as of December 31, 2012 to $0 as of December 31, 2013. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.
	Changes in the recurring fair value measurements of financial assets and liabilities using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 were as follows:
		2013			2012
	Beginning balance	$	1,370		$	—
	Contingent consideration recorded at acquisition	—			1,370
	Fair value adjustments	(1,370		)	—
	Ending balance	$	—		$	1,370

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 8 - PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following at December 31 (in thousands):
		2013			2012
	Laboratory equipment	$	27,519		$	21,155
	Leasehold improvements	22,881			16,885
	Computer equipment	7,415			7,068
	Purchased software	18,843			15,756
	Furniture and fixtures	4,903			4,834
	Assets on loan/rental	4,027			3,499
	Capital lease equipment	116			116
		85,704			69,313
	Less: Accumulated amortization and depreciation	(52,911		)	(43,084		)
		$	32,793		$	26,229
	Depreciation expense was $10.2 million, $8.8 million, and $7.8 million for the years ended December 31, 2013, 2012, and 2011, respectively.

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	NOTE 9 - GOODWILL AND OTHER INTANGIBLE ASSETS
	On July 11, 2012, the Company completed the acquisition of GenturaDx.  As a result, the Company recorded approximately $8.3 million of goodwill and approximately $40.1 million of other identifiable intangible assets.   For impairment testing purposes, the Company has assigned all of the GenturaDx goodwill to the ARP segment.   This goodwill is not expected to be deductible for tax purposes.
	The changes in the carrying amount of goodwill during the period are as follows (in thousands):
		2013			2012
	Balance at beginning of year	$	51,128		$	42,763
	Acquisition of GenturaDx	—			8,292
	Foreign currency translation adjustments	(390		)	73
	Balance at end of year	$	50,738		$	51,128
	The current in process research and development projects are scheduled to be completed in 2014. The estimated costs to complete these projects are between $5.0 million and $8.0 million.
	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2012
	Balance at December 31, 2011	$	30,000		$	7,981		$	1,933		$	631		$	40,545
	Additions due to acquisition of GenturaDX	—			—			—			40,100			40,100
	Write-off of  IP R&D projects	—			—			—			(118		)	(118		)
	Foreign currency translation adjustments	30			5			8			14			57
	Balance at December 31, 2012	30,030			7,986			1,941			40,627			80,584
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2011	(9,999		)	(768		)	(341		)	—			(11,108		)
	Amortization expense	(3,187		)	(790		)	(266		)	—			(4,243		)
	Foreign currency translation adjustments	(7		)	(2		)	(6		)	—			(15		)
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Net balance at December 31, 2012	$	16,837		$	6,426		$	1,328		$	40,627		$	65,218
	Weighted average life (in years)	10			11			9
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off/Impairment	(214		)	(7		)	(20		)	(454		)	(695		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	29,676			7,952			1,880			40,100			79,608
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
	The estimated aggregate amortization expense for the next five years and thereafter is as follows (in thousands):
	2014	$	3,917
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,848
		20,195
	IPR&D	40,100
		$	60,295

OTHER_COMPREHENSIVE_LOSS_INCOM

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME	12 Months Ended
	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	NOTE 10 — OTHER COMPREHENSIVE (LOSS) INCOME
	Comprehensive (loss) income represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive (loss) income for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2012	$	1,100		$	1		$	1,101
	Other comprehensive (loss) income before reclassifications	(681		)	11			(670		)
	Amounts reclassified from accumulated other comprehensive income	—			(12		)	(12		)
	Net current-period other comprehensive loss	(681		)	(1		)	(682		)
	Ending balance, December 31, 2013	$	419		$	—		$	419
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Twelve Months Ended December 31, 2013
		Before Tax			Tax Benefit			Net of Tax
	Foreign currency translation adjustments	$	(681	)	$	—		$	(681	)
	Unrealized (losses) gains on available-for-sale investments	(2		)	1			(1		)
	Other comprehensive (loss) income	$	(683	)	$	1		$	(682	)

OTHER_ASSETS

OTHER ASSETS	12 Months Ended
	Dec. 31, 2013
Other Assets [Abstract]	'
OTHER ASSETS	'
	NOTE 11 – OTHER ASSETS
	Other assets consisted of the following at December 31 (in thousands):
		2013			2012
	Purchased technology rights (net of accumulated amortization of $3,965 and $2,390 in 2013 and 2012, respectively)	$	2,943		$	3,765
	Cost-method investments	1,000			5,081
	Other	959			556
		4,902			9,402
	Less: Current portion	(965		)	(939		)
		$	3,937		$	8,463
	For the years ended December 31, 2013 and 2012, the Company recognized amortization expense related to the amortization of purchased technology rights of approximately $1,639,000 and $1,304,000, respectively.  Future amortization expense is estimated to be $1,345,000 in 2014, $408,000 in 2015, $182,000 in 2016, $161,000 in 2017, $103,000 in 2018 and $744,000 thereafter.
	Non-Marketable Securities and Other-Than-Temporary Impairment
	The Company owns a minority interest in a private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012.  This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee as the Company owns less than 20% of the voting equity and the investee is not publicly traded.
	The Company's other minority interest in a private company was acquired by a third party in July 2013 and, as a result, the Company's minority interest in that private company was sold. The Company realized a gain of $5.4 million on this minority interest investment in the third quarter of 2013.
	The Company regularly evaluates the carrying value of cost-method investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investments. The primary indicators the Company utilizes to identify these events and circumstances are the investee's ability to remain in business, such as the investee's liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income, net in the Consolidated Statements of Operations. As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, these cost-method investments are classified within Level 3 of the fair value hierarchy. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost-method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical.

ACCRUED_WARRANTY_COSTS

ACCRUED WARRANTY COSTS	12 Months Ended
	Dec. 31, 2013
Product Warranties Disclosures [Abstract]	'
ACCRUED WARRANTY COSTS	'
	NOTE 12 - ACCRUED WARRANTY COSTS
	Sales of certain of the Company’s systems are subject to a warranty.  System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment.  The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data.  The actual warranty expense could differ from the estimates made by the Company based on product performance.  Warranty expenses are evaluated and adjusted periodically.
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2010	$	477
	Warranty expenses	(1,131		)
	Accrual for warranty costs	1,335
	Accrued warranty costs at December 31, 2011	681
	Warranty expenses	(1,119		)
	Accrual for warranty costs	1,041
	Accrued warranty costs at December 31, 2012	603
	Warranty expenses	(1,150		)
	Accrual for warranty costs	1,268
	Accrued warranty costs at December 31, 2013	$	721

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 13 - INCOME TAXES
	The components of income before income taxes for the years ended December 31 are as follows (in thousands):
		2013				2012				2011
	Domestic	$	20,301			$	28,241			$	26,373
	Foreign	(8,877		)		(5,461		)		(2,444		)
	Total	$	11,424			$	22,780			$	23,929
	The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands):
		2013				2012				2011
	Current:
	Federal	$	4,024			$	4,158			$	8,630
	Foreign	406				(129		)		494
	State	720				928				1,420
	Total current	$	5,150			$	4,957			$	10,544
	Deferred:
	Federal	(381		)		3,945				(604		)
	Foreign	(1		)		1,179				(207		)
	State	(440		)		292				(278		)
	Total deferred	(822		)		5,416				(1,089		)
	Total provision for income taxes	$	4,328			$	10,373			$	9,455
	The provision for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):
		Year Ended December 31,
		2013			2012			2011
	Statutory tax rate	35	%		35	%		35	%
	State taxes, net of federal benefit	0.3	%		3.9	%		2.7	%
	Permanent items	(4.6	)%		2	%		5.3	%
	Effect of foreign operations	3.1	%		0.5	%		(0.4	)%
	Research and incentive tax credit generated	(43.0	)%		(7.1	)%		(2.5	)%
	Valuation allowance	42.6	%		11.6	%		(1.3	)%
	Income tax reserves	4.9	%		0.1	%		0.5	%
	Other	(0.4	)%		(0.5	)%		0.2	%
		37.9	%		45.5	%		39.5	%
	The federal research and experimentation tax credit was extended on January 2, 2013 by the signing of the American Taxpayer Relief Act of 2012 (the Act). The Act retroactively extended this credit from January 1, 2012 through December 31, 2013. Because the Act was enacted during 2013, an income tax benefit of $664,000 related to the 2012 research and experimentation tax credit is reflected in the 2013 income tax provision along with an income tax benefit of $1.3 million related to the 2013 research and experimentation credit. The federal research and experimentation tax credit expired on December 31, 2013 and, if not renewed under similar terms as in prior years, will impact the Company's future financial results.
	The Company accounts for income taxes using the liability method in accordance with ASC 740 "Income Taxes". Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands):
		2013				2012				2011
	Deferred tax assets:
	Current deferred tax assets
	Accrued liabilities and other	$	7,114			$	6,082			$	6,830
	Deferred revenue	1,820				—				—
	Gross current deferred tax assets	8,934				6,082				6,830
	Valuation allowance	(792		)		(536		)		(839		)
	Net current deferred tax assets	8,142				5,546				5,991
	Noncurrent deferred tax assets
	Net operating loss and credit carryforwards	68,973				67,018				48,633
	Deferred revenue	927				2,729				2,867
	Depreciation and amortization	7,899				8,370				7,568
	Stock compensation	4,871				5,851				5,904
	Gross noncurrent deferred tax assets	82,670				83,968				64,972
	Valuation allowance	(49,294		)		(44,132		)		(39,229		)
	Net noncurrent deferred tax assets	$	33,376			$	39,836			$	25,743
	Deferred tax liabilities:
	Current deferred tax liabilities
	Accrued liabilities and other	$	(877	)		$	(763	)		$	—
	Total current deferred tax liabilities	(877		)		(763		)		—
	Net current deferred tax asset	7,265				4,783				5,991
	Noncurrent deferred tax liabilities
	Depreciation and amortization	(19,788		)		(22,784		)		(9,352		)
	Stock compensation	(53		)		(61		)		(92		)
	Acquired intangibles	(1,622		)		(2,631		)		(3,482		)
	Total noncurrent deferred tax liabilities	(21,463		)		(25,476		)		(12,926		)
	Net noncurrent deferred tax asset	11,913				14,360				12,817
	Net deferred tax assets	$	19,178			$	19,143			$	18,808
	Under ASC 740, the Company can only recognize a deferred tax asset to the extent that it is “more likely than not” that these assets will be realized. In evaluating the need for a valuation allowance, all available evidence, both positive and negative, is considered to determine whether, based on the weight of that evidence, a valuation allowance is needed. The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of deferred tax liabilities that can be used to realize deferred tax assets. The valuation allowance increased approximately $5.4 million in 2013 from 2012 primarily due to the Canadian and Australian subsidiaries which have a full valuation allowance recorded against their net deferred tax assets.
	At December 31, 2013, the Company had gross federal, state and foreign net operating loss carryforwards of approximately $79.9 million, $53.8 million, and $28.5 million respectively. These losses expire beginning in 2015, except for $4.9 million of losses that have unlimited carryforward periods. Approximately $20.1 million of the federal net operating loss carryforward is attributable to excess employee stock option deductions, the benefit from which will be allocated to additional paid-in capital rather than current earnings if subsequently realized. Federal and state net operating losses of approximately $59.8 million and $53.8 million, respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the "change of ownership" provisions of Section 382 of the Internal Revenue Code of 1986 and similar state provisions. The Company has federal, state, and foreign credit carryforwards of approximately $10.4 million, $1.8 million, and $10.9 million, respectively. These credits begin to expire in 2018, except for approximately $4.4 million which have an indefinite carryforward period. Approximately $6.9 million of the federal credits are attributable to excess employee stock option deductions, the benefit of which has been allocated to additional paid-in capital rather than current earnings when subsequently realized. State credits of approximately $1.1 million were acquired as part of the acquisition of GenturaDx in 2012 and are subject to annual limitations due to the "change of ownership" provisions of Section 382 of the Internal Revenue Code of 1986 and similar California state tax provisions. In addition, the Company has a gross scientific research and experimental development pool in Canada of approximately $57.2 million which has an indefinite carryforward period.
Undistributed earnings of the Company's foreign subsidiaries are considered permanently reinvested and, accordingly, no provision for U.S. federal or state income taxes has been provided thereon.  The cumulative amount of undistributed earnings of the Company's non-US subsidiaries was approximately $920,000 at December 31, 2013, $1.2 million at December 31, 2012, and $2.1 million at December 31, 2011.  Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable at this time because such liability, if any, is dependent upon circumstances existing if and when remittance occurs.
As of December 31, 2013 and December 31, 2012, the Company had recorded gross unrecognized tax benefits of approximately $2.3 million and $1.8 million, respectively.  All of the unrecognized tax benefits as of December 31, 2013, if recognized, would impact the effective tax rate.  The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense.  During the years ended December 31, 2013 and 2012, the Company recognized approximately $14,000 and $14,000 in tax related interest and penalties, respectively.  Reserves for interest and penalties as of December 31, 2013 and 2012 are not significant as the Company has net operating loss carryovers.
A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):
	2013				2012
Balance at beginning of year	$	1,760			$	1,370
Additions based on tax positions related to the current year	335				390
Additions for tax positions of prior years	238				—
Reductions for tax positions of prior years	—				—
Settlements	—				—
Lapse of statute of limitations	—				—
Cumulative translation adjustment	—				—
Balance at end of year	$	2,333			$	1,760
As of December 31, 2013, there were no unrecognized tax benefits that the Company expects would change significantly over the next 12 months.
The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations.  In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2009 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2009 tax year and make adjustments to these net operating loss carryforwards.  There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. The Company is currently under audit in Canada for its scientific research and experimental development pool claims for the 2009 through 2011 tax years. Although the Company does not expect a material adjustment, the outcome of the audit is not known at this time.  The Company is not under audit in any other major taxing jurisdictions at this time.

LONGTERM_DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
LONG-TERM DEBT	'
	NOTE 14 - LONG-TERM DEBT
	On December 31, 2013, long-term debt consisted of a loan payable to TPC valued at $0.5 million and the related short term payable of $1.2 million.
	On December 12, 2003, Tm Bioscience entered into an agreement with the Ministry of Industry of the government of Canada under which the Government agreed to invest up to $7.3 million (Cdn) relating to the development of several genetic tests.  This agreement was amended in March 2009.  Funds were advanced from Technology Partnerships Canada (TPC), a special operating program.  The actual payments received by the Company were predicated on eligible expenditures made during the amended project period, which ended July 31, 2008.  As of December 31, 2013, the Company had received $4.5 million from TPC ($4.9 million (Cdn)), which is expected to be repaid along with approximately $1.5 million of imputed interest for a total of approximately $6.1 million ($6.5 million (Cdn)).  Approximately $4.4 million ($4.7 million (Cdn)) of the interest and advances has been repaid as of December 31, 2013.
	Tm Bioscience agreed to repay the TPC funding through a royalty on revenues.  This liability was assumed by the Company as part of the acquisition of TM Bioscience and the liability was recorded at fair value as of the date of acquisition.  This liability is subject to adjustments for foreign currency translation effects as it is a foreign currency denominated balance.  Royalty payments commenced in 2007 at a rate of 1% of total LMD revenue and at a rate of 2.5% for 2008 and thereafter.  Aggregate royalty repayment will continue until total advances plus imputed interest has been repaid or until December 31, 2016, whichever is earlier.  The repayment obligation expires on December 31, 2016 and any unpaid balance will be cancelled and forgiven on that date.  Should the term of repayment be shorter than expected due to higher than expected assay revenue, the effective interest rate would increase as repayment is accelerated. Repayments denominated in U.S. Dollars are currently projected to be as shown in the table below, but actual future sales generating a repayment obligation will vary from this projection and are subject to the risks and uncertainties described elsewhere in this report, including under “Risk Factors” and “Safe Harbor Cautionary Statement.” Furthermore, payments reflected in U.S. Dollars are subject to adjustment based upon applicable exchange rates as of the reporting date.
	Estimated repayments on the debt for the next five years and thereafter are as follows (in thousands):
	2014	$	1,194
	2015	469
	2016	—
	2017	—
	2018	—
	Thereafter	—
		$	1,663
	Less: Amount representing implied interest	(6		)
	Total principal repayments	$	1,657
	Discount	—
	Total long-term debt	$	1,657
	Less: Current portion of long-term debt	(1,194		)
		$	463
	In 2013 and 2012, the Company had imputed interest expense related to its long-term debt of $48,000 and $89,000, respectively.  The effective interest rate was 3.90% as of December 31, 2013 and 2012.  At December 31, 2013 and 2012, the fair value of the Company’s long-term debt was approximately $1.5 million and $2.5 million, respectively.  The Company’s long-term debt is classified as a Level 3 instrument and the Company has used a discounted cash flow (DCF) model to determine the estimated fair value as of December 31, 2013 and 2012.  The assumptions used in preparing the DCF model include estimates for (i) the amount and timing of future interest and principal payments and (ii) the rate of return indicative of the investment risk in the ownership of the TPC debt.  In making these assumptions, the Company considered relevant factors including the likely timing of principal repayments and the probability of full repayment considering the timing of royalty payments based upon total revenue.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
NET INCOME PER SHARE	'
	NOTE 15 - NET INCOME PER SHARE
	The following table sets forth the computation of basic and diluted net income per share (in thousands, except share and per share data):
		Year Ended December 31,
		2013		2012		2011
	Numerator:
	Net income	$	7,096	$	12,407	$	14,474
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	40,799		40,927		41,262
	Effect of dilutive securities:
	Stock options and awards	1,187		957		1,275
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	41,986		41,884		42,537
	Basic net income per share	$	0.17	$	0.3	$	0.35
	Diluted net income per share	$	0.17	$	0.3	$	0.34
	Restricted stock awards (RSAs) and stock options to acquire 381,000, 364,000, and 141,000 shares for the years ended December 31, 2013, 2012 and 2011, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.

STOCKHOLDERS_EQUITY_EMPLOYEE_B

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION	'
	NOTE 16 - STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION
	Preferred Stock
	The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders.  At December 31, 2013 and 2012, there was no preferred stock issued and outstanding.
	Stock-Based Compensation
	At December 31, 2013, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Second Amended and Restated 2006 Equity Incentive Plan (the “Equity Incentive Plan”) which was approved at the Company’s Annual Meeting on May 25, 2006 and amended at the Company’s Annual Meetings on each of May 21, 2009 and May 17, 2012.  No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (the “2000 Plan”), the 2001 Broad-Based Stock Option Plan (the “2001 Plan”) or the 2006 Management Stock Purchase Plan (the “MSPP”), which was terminated effective March 7, 2012. In addition, at December 31, 2013, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (the "ESPP"), which was approved at the Company's Annual Meeting on May 17, 2012.
	Equity Incentive Plans
	Under the Company’s Equity Incentive Plan, 2000 Plan, and the 2001 Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted share units (RSUs) and options to purchase shares of common stock.  The options, RSAs, and RSUs generally vest in installments over a four to five year period, and the options expire either five or ten years after the date of grant.  Under the Equity Incentive Plan, certain employees, directors of, and consultants to the Company are eligible to be granted RSAs, RSUs, and options to purchase common stock. The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15%, of their base salary through the purchase of the Company's common stock, discounted by 15%. As of December 31, 2013, there were approximately 3.9 million shares authorized for future issuance under the Company’s Equity Incentive Plan and approximately 393,000 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below.
	The Equity Incentive Plan, the ESPP, the 2000 Plan and the 2001 Plan are administered by the Compensation Committee of the Board of Directors.  The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option award exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant.  Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs.
	On March 9, 2010, March 25, 2011, March 7, 2012 and March 19, 2013 the Compensation Committee of the Board adopted the Luminex Corporation 2010 Long Term Incentive Plan (the “2010 LTIP”), the Luminex Corporation 2011 Long Term Incentive Plan (the “2011 LTIP”) the the Luminex Corporation 2012 Long Term Incentive Plan (the "2012 LTIP") and the 2013 Long Term Incentive Plan (the "2013 LTIP"), respectively.  Awards under all of the LTIP plans were granted by the Compensation Committee in the form of RSUs and are to be treated as Performance Awards under the Equity Incentive Plan.  Grants of RSUs under the LTIP plans shall initially be unvested and represent the maximum amount of shares that participants may receive under the plan, assuming achievement of the maximum level of performance goals established for the grant, and subject to adjustment for certain transactions and other extraordinary or non-recurring events that may affect Luminex or its financial performance.
	On March 9, 2010, the Company’s Chief Executive Officer was granted an award for an unvested RSU under the 2010 LTIP for up to $2,200,000 worth of shares (grant date fair value) of Luminex common stock, and the Company’s Chief Financial Officer was granted an award for an unvested RSU under the 2010 LTIP for up to $825,000 worth of shares (grant date fair value) of Luminex common stock.  The actual maximum number of shares of 132,930 shares and 49,848 shares for the CEO and CFO, respectively, was determined on March 11, 2010, based upon the closing price of the stock on that date.  Performance goals under the grants are based on the following components, with the following weights given to each: 50% on the trading price of Luminex common stock at the end of the performance period and 50% on Luminex’s operating cash flows per diluted share at the end of the performance period.
	The 2010 LTIP performance goals are as described below:
	•	Partial or complete achievement of the trading price goal is dependent upon the average closing price of Luminex’s common stock for the twenty consecutive trading days ending December 31, 2012, inclusive, subject to certain adjustments as described in the 2010 LTIP. There is a range of trading price targets as follows: a minimum threshold of $22.22 per share, a target of $25.25 per share, and a maximum goal of $40.09 per share. No shares were earned for this goal under the 2010 LTIP.
	•	Partial or complete achievement of the operating cash flow goal is dependent upon the total operating cash flows per diluted share for the four quarters ended December 31, 2012, as further described in the 2010 LTIP. Total operating cash flows means Luminex’s GAAP net cash provided by operating activities as shown on its financial statements for the 12 month period ended December 31, 2012, as further described in the 2010 LTIP. There is a range of targets as follows: a minimum threshold of $0.212 per share, a target of $0.241 per share, and a maximum goal of $0.382 per share. The final determination and certification of the shares earned for this goal was made by the compensation committee of the Board of Directors on February 27, 2013 resulting in the Chief Executive Officer earning 18,835 shares and the Chief Financial Officer earning 7,063 shares.
	On March 25, 2011, the Company’s Chief Executive Officer was granted an award for an unvested RSU under the 2011 LTIP for up to $2,200,000 worth of shares (grant date fair value) of Luminex common stock, and the Company’s Chief Financial Officer was granted an award for an unvested RSU under the 2011 LTIP for up to $825,000 worth of shares (grant date fair value) of Luminex common stock.  The actual maximum number of shares of 119,304 shares and 44,740 shares for the CEO and CFO, respectively, was determined on March 25, 2011, based upon the closing price of the stock on that date.  Performance goals under the grants are based on the following components, with the following weights given to each: 50% on the trading price of Luminex common stock at the end of the performance period and 50% on Luminex’s total income from operations per diluted share at the end of the performance period.
	The 2011 LTIP performance goals are as described below:
	•	Partial or complete achievement of the trading price goal is dependent upon the average closing price of Luminex’s common stock for the twenty consecutive trading days ending December 31, 2013, inclusive, subject to certain adjustments as described in the 2011 LTIP. There is a range of trading price targets as follows: a minimum threshold of $28.50 per share, a target of $32.38 per share, and a maximum goal of $51.42 per share. No shares were earned for this goal under the 2011 LTIP.
	•	Partial or complete achievement of the income from operations goal is dependent upon the total income from operations per diluted share for the year ended December 31, 2013, as further described in the 2011 LTIP. Total income from operations means Luminex’s income from operations as reflected on the Company’s Consolidated Statement of Comprehensive Operations for the year ended December 31, 2013, as further described in the 2011 LTIP. There is a range of targets as follows: a minimum threshold of $0.73 per share, a target of $0.81 per share, and a maximum goal of $1.19 per share. The final determination and certification of the shares earned for this goal will be made by the compensation committee after the filing of this Annual Report on Form 10-K.
	On March 7, 2012, the Company’s Chief Executive Officer was granted an award for an unvested RSU under the 2012 LTIP for up to $2,200,000 worth of shares (grant date fair value) of Luminex common stock, and the Company’s Chief Financial Officer was granted an award for an unvested RSU under the 2012 LTIP for up to $550,000 worth of shares (grant date fair value) of Luminex common stock.  The actual maximum number of shares of 98,434 shares and 24,608 shares for the CEO and CFO, respectively, was determined on March 7, 2012, based upon the closing price of the stock on that date.  Performance goals under the grants are based on the following components, with the following weights given to each: 50% on the trading price of Luminex common stock at the end of the performance period and 50% on Luminex’s total income from operations at the end of the performance period.
	The 2012 LTIP performance goals are as described below:
	•	Partial or complete achievement of the trading price goal is dependent upon the average closing price of Luminex’s common stock for the twenty consecutive trading days ending December 31, 2014, inclusive, subject to certain adjustments as described in the 2012 LTIP. There is a range of trading price targets as follows: a minimum threshold of $29.29 per share, a target of $32.54 per share, and a maximum goal of $39.75 per share.
	•	Partial or complete achievement of the total income from operations goal is dependent upon the total income from operations for the year ended December 31, 2014, as further described in the 2012 LTIP. Total income from operations means Luminex’s income from operations as reflected on the Company’s Consolidated Statement of Comprehensive Operations for the year ended December 31, 2014, as further described in the 2012 LTIP. There is a range of targets as follows: a minimum threshold of $58,663,000, a target of $67,286,000, and a maximum goal of $85,831,000.
	On March 19, 2013, the Company’s Chief Executive Officer was granted an award for an unvested RSU under the 2013 LTIP for up to $1,200,000 worth of shares (grant date fair value) of Luminex common stock, and the Company’s Chief Financial Officer was granted an award for an unvested RSU under the 2013 LTIP for up to $300,000 worth of shares (grant date fair value) of Luminex common stock.  The actual maximum number of shares of 71,727 shares and 17,931 shares for the CEO and CFO, respectively, was determined on March 19, 2013, based upon the closing price of the stock on that date.  The performance goal under the grants is based on Luminex’s fully diluted earnings per share at the end of the performance period (Adjusted EPS Goal).
	The 2013 LTIP performance goal is as described below:
	•	Partial or complete achievement of the Adjusted EPS Goal is dependent upon Luminex's fully diluted earnings per share for the year ended December 31, 2015, as further described in the 2013 LTIP. There is a range of targets as follows: a minimum threshold of $1.06 per share, a target of $1.18 per share, and a maximum goal of $1.36 per share.
	In the event that a participant achieves less than the maximum level of the performance goal, the total number of shares represented by such RSU shall be reduced to reflect where actual performance lies in the range of performance goals and weighted aggregate corresponding payout opportunities established for the grant. Calculation of shares between threshold and maximum performance shall be determined based on straight-line interpolation.
	Accounting for Stock Compensation
	Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options and market value on the date of grant for RSAs.  The fair values of stock are amortized as compensation expense on a straight-line basis over the vesting period of the grants.
	In accordance with ASC 718 the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected term is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options.  The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has never paid cash dividends and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.  The assumptions used are summarized in the following table:
		2013				2012				2011
	Dividend yield	—		%		—		%		—		%
	Expected volatility	0.5				0.5				0.5
	Risk-free rate of return	1.2		%		1.2		%		2.3		%
	Expected life	7 years				7 years				7 years
	Weighted average fair value at grant date	$	8.79			$	7.78			$	7.67
	As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods.
	The Company’s stock option activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
	Stock Options	Shares			Weighted Average Exercise Price				Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
		(in thousands)
	Outstanding at December 31, 2010	2,367			$	10.82
	Granted	84			18.26
	Exercised	(304	)		11.65
	Cancelled or expired	(127	)		23.74
	Outstanding at December 31, 2011	2,020			$	10.19
	Granted	160			22.53
	Exercised	(487	)		7.22
	Cancelled or expired	(17	)		20.37
	Outstanding at December 31, 2012	1,676			$	12.13
	Granted	159			17.24
	Exercised	(835	)		9.06
	Cancelled or expired	(33	)		19.8
	Outstanding at December 31, 2013	967			$	15.35			4.65		$	4,417
	Vested at December 31, 2013 and expected to vest	965			$	15.34			4.64		$	4,413
	Exercisable at December 31, 2013	701			$	13.91			3.14		$	4,066
	During the years ended December 31, 2013, 2012 and 2011, the total exercise intrinsic value of stock options exercised was $8.7 million, $6.9 million and $2.9 million, respectively, and the total fair value of stock options that vested was $2.5 million, $2.0 million and $1.9 million, respectively.  Exercise intrinsic value represents the difference between the market value of the Company's common stock at the time of exercise and the strike price of the stock option. The Company had $1.9 million of total unrecognized compensation costs related to stock options at December 31, 2013 that are expected to be recognized over a weighted-average period of 1.7 years.
	The Company’s restricted share activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
	Restricted Stock Awards	Shares			Weighted Average Grant Price
		(in thousands)
	Non-vested at December 31, 2010	1,093			$	16.41
	Granted	239			18.73
	Vested	(362	)		16.11
	Cancelled or expired	(67	)		16.57
	Non-vested at December 31, 2011	903			$	17.13
	Granted	329			22.5
Vested	(339	)		16.75
Cancelled or expired	(75	)		18.59
Non-vested at December 31, 2012	818			$	19.32
Granted	354			17.28
Vested	(267	)		18.83
Cancelled or expired	(79	)		19.15
Non-vested at December 31, 2013	826			$	18.62
Restricted Stock Units	Shares			Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
	(in thousands)
Non-vested at December 31, 2010	768
Granted	269
Vested	(58	)
Cancelled or expired	(152	)
Non-vested at December 31, 2011	827
Granted	246
Vested	(80	)
Cancelled or expired	(118	)
Non-vested at December 31, 2012	875
Granted	199
Vested	(79	)
Cancelled or expired	(162	)
Non-vested at December 31, 2013	833			1.82		$	16,167
Vested at December 31, 2013 and expected to vest	578			1.81		$	10,439
Exercisable at December 31, 2013	40			0		$	766
As of December 31, 2013, there was $17.1 million of unrecognized compensation cost related to RSAs and RSUs.  That cost is expected to be recognized over a weighted average-period of 2.6 years.  The total fair value of restricted shares vested during the year ended December 31, 2013, 2012 and 2011 was $7.2 million, $8.3 million, and $7.3 million, respectively.
RSAs and RSUs may be granted at the discretion of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2013, the Company awarded 353,537 shares of restricted stock awards, which had a fair value at the date of grant ranging from $16.18–$18.11. During the year ended December 31, 2012, the Company awarded 329,096 shares of restricted stock awards, which had a fair value at the date of grant ranging from $17.26–$22.71. During the year ended December 31, 2011, the Company awarded 238,812 shares of restricted stock awards, which had a fair value at the date of grant ranging from $18.26–$21.00.  During the year ended December 31, 2013, the Company awarded 199,051 shares of restricted stock units, which had a fair value at the date of grant ranging from $16.73–$20.51.  During the year ended December 31, 2012, the Company awarded 246,205 shares of restricted stock units, which had a fair value at the date of grant ranging from $16.16–$23.82.  During the year ended December 31, 2011, the Company awarded 268,882 shares of restricted stock units, which had a fair value at the date of grant ranging from $18.26–$20.92. Compensation under these restricted stock awards and units was charged to expense over the restriction period and amounted to $7.5 million, $8.4 million, and $10.2 million in 2013, 2012 and 2011, respectively.
There were no significant stock compensation costs capitalized into assets as of December 31, 2013, 2012 or 2011.
The Company received $7.6 million, $3.5 million, and $3.5 million for the exercise of stock options during the years ended December 31, 2013, 2012 and 2011, respectively.  Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan, 2000 Plan and 2001 Plan from reserves upon the exercise of stock options and vesting of RSAs.
Employee Savings Plans and Other Benefit Plans
Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2013, 2012 and 2011, each employee could contribute a percentage of compensation up to a maximum of $17,500, $17,000, and $16,500 per year, respectively, with the Company matching 50% of each employee’s contributions.  Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees.  All Canadian employees are eligible to participate in the plan.  The Company’s contributions to these plans for 2013, 2012 and 2011 were $2.4 million, $2.1 million, and $1.6 million, respectively.
Several of the Company’s Netherlands employees are covered by a defined benefit plan.  The cost and total liability to the Company is not significant.  Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan.
Employee Stock Purchase Plan
In May 2012, the Company's stockholders approved the ESPP Plan, which provides for the granting of up to 500,000 shares of the Company's common stock to eligible employees. The ESPP period is semi-annual and allows participants to purchase the Company's common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. The first plan option period began on July 1, 2012. As of December 31, 2013 and 2012, 106,522 shares and 35,296 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.4 million and $0.2 million for 2013 and 2012, respectively.
The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions:
	2013
Assumptions:
Risk-free interest rates	.09% to 0.15%
Expected life	0.5 years
Expected volatility	0.51
Dividend yield	—	%
The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands):
	Year Ended December 31,
	2013				2012				2011
Cost of revenue	$	856			$	947			$	917
Research and development	2,553				2,034				2,126
Selling, general and administrative	5,812				6,934				8,374
Stock-based compensation costs reflected in net income	$	9,221			$	9,915			$	11,417
Reserved Shares of Common Stock
At December 31, 2013 and 2012, the Company had reserved 4,275,753 and 4,827,116 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2013:
	Options Outstanding			Shares Available for Future Issuance			Total Shares Reserved
2000 Plan	97,000			—			97,000
2001 Plan	27,060			—			27,060
2006 Equity Incentive Plan	1,715,876			3,882,275			5,598,151
ESPP Plan	—			393,478			393,478
Balthrop Option	200,000			—			200,000
	2,039,936			4,275,753			6,315,689

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 17 - COMMITMENTS AND CONTINGENCIES
	Lease Arrangements
	The Company has operating leases related primarily to its office and manufacturing facilities with original lease periods of up to ten years. Rental and lease expense for these operating leases for the years 2013, 2012 and 2011 totaled approximately $5.1 million, $5.5 million, and $3.6 million, respectively.
	In the fourth quarter of 2012, the Company ceased using the Hayward, California facility, whose operating lease commitment was acquired under the GenturaDx acquisition in July 2012. The Company has accrued a liability based upon the estimated fair value of the costs that will continue to be incurred under the lease, including an estimate of sublease rental income.
	Minimum annual lease commitments as of December 31, 2013 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands):
	2014	$	4,120
	2015	2,785
	2016	1,811
	2017	1,498
	2018	1,310
	Thereafter	5,516
	Total	$	17,040
	These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above.  These amounts are recorded to expense on a straight-line basis over the life of the lease.  In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives.
	Non-Cancellable Purchase Commitments
	As of December 31, 2013 the Company had approximately $12.1 million in purchase commitments with several of its inventory suppliers. These commitments require delivery of minimum amounts of components through 2018.
	Employment Contracts
	The Company has entered into employment contracts with certain of its key executives.  Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason.
	Legal Proceedings
	On August 30, 2012 Abbott Laboratories (Abbott) was named as a defendant in the complaint filed by ENZO Life Sciences, Inc. (ENZO) in U.S. District Court in Delaware for alleged infringement of its US Patent 7,064,197 as a result of Abbott's distribution of the Company's xTAG Respiratory Viral Panel.  The Company and Abbott have entered into an agreement requiring Luminex to defend and indemnify Abbott for any alleged infringement resulting from its distribution of the Respiratory Viral Panel. The complaint seeks unspecified monetary damages and injunctive relief.  Abbott filed an answer to the complaint on October 15, 2012.  On November 30, 2012, the Company intervened in the lawsuit. On January 2, 2013 ENZO filed additional claims against the Company, alleging infringement of US Patent 7,064,197 resulting from the Company's sale of its xTAG, FlexScript LDA, SelecTAG, and xMAP Salmonella Serotyping Assay products and alleging infringement of US Patent 8,097,405 resulting from the Company's sale of Multicode products.  The Company filed an answer to ENZO's additional claims on January 28, 2013.  On October 2, 2013 ENZO filed additional claims against the Company, alleging infringement of U.S. Patent 6,992,180 resulting from the Company’s sale of Multicode products.  The Company filed an answer to ENZO’s additional claims on October 21, 2013. A trial date has not been set. The parties to the lawsuit have engaged in the discovery process.
	On November 1, 2013 Irori Technologies, Inc. filed a complaint against the Company in U.S. District Court in the Southern District of California, alleging infringement of its U.S. Patent numbers  6,372,428, 6,416,714, and 6,352,854 resulting from the Company’s sale of its  xMAP and xTAG based products.  The complaint seeks unspecified monetary damages and injunctive relief. The Company filed a motion to dismiss on January 9, 2014.  Irori filed its response to our motion to dismiss on February 7, 2014.  The matter is currently before the court.  A trial date has not been set.
	When and if it appears probable in management's judgment that the Company will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, liabilities will be recorded in the financial statements and charges will be recorded against earnings.  There can be no assurance that the Company will successfully defend this suit or that a judgment against the Company would not materially adversely affect operating results.
	Other Matters
	In January 2013, the Company finalized the termination of its molecular diagnostics distribution agreements and an expense of $7.0 million was recorded in selling, general and administrative expenses in the first quarter of 2013. All payments were made in the second quarter of 2013.

GUARANTEES

GUARANTEES	12 Months Ended
	Dec. 31, 2013
Guarantees [Abstract]	'
GUARANTEES	'
	NOTE 18 - GUARANTEES
	The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 19 – SEGMENT AND GEOGRAPHIC INFORMATION
	The Chief Operating Decision Maker (CODM) is Luminex’s Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment using information about its revenue and projections. The Company’s reporting segments reflect the nature of the products offered to customers and the markets served and are comprised of the following:
	TSP segment - represents the Company’s base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items.
	ARP segment - primarily involved in the development and sale of assays on xMAP technology for use on Luminex’s installed base of systems, as well as the sale of automated punching systems.
	Intersegment sales are recorded at fixed prices which approximate the prices charged to third party strategic partners and are not a measure of segment operating earnings.   Intersegment sales of approximately $10.7 million, $11.7 million, and $8.8 million for the years ended December 31, 2013, 2012 and 2011 have been eliminated upon consolidation, respectively.
	The Company reclassified certain 2012 amounts in the accompanying consolidated financial statements to conform to the 2013 presentation. These reclassifications include $2.1 million of ARP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment research and development expenses for the year ended December 31, 2012 and $12.7 million of TSP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment selling, general and administrative expenses for the year ended December 31, 2012. These reclassifications had no effect on the Company's consolidated comprehensive income or stockholders' equity.
	Following is selected information for the years ended December 31, 2013 and 2012 or as of December 31, 2013 and 2012 (in thousands):
		2013							2012
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment				Consolidated
	Revenues from external customers	$	132,023	$	81,400		$	213,423	$	121,032	$	81,550			$	202,582
	Depreciation and amortization	7,990		7,932			15,922		6,930		7,434				14,364
	Operating profit (loss)	33,761		(28,994		)	4,767		27,829		(5,113		)		22,716
	Segment assets	154,174		151,872			306,046		140,896		156,279				297,175
	The table below provides information regarding long-term assets and product revenues from the Company’s sales to customers within the United States and in foreign countries for the years ended December 31 (in thousands):
		Sales to Customers							Long-Term Assets
		2013		2012			2011		2013				2012					2011
	Domestic	$	178,276	$	167,924		$	152,480	$	109,448			$	113,700				$	66,094
	Foreign:
	Europe	16,690		17,376			16,029		1,012				1,433					978
	Asia	12,287		10,877			9,481		234				212					280
	Canada	3,025		3,753			2,892		46,535		[1]		48,929				[1]	52,028		[1]
	Australia	1,299		963			1,344		2,443		[2]		4,108				[3]	4,252		[3]
	Other	1,846		1,689			2,113		4				16					38
		$	213,423	$	202,582		$	184,339	$	159,676			$	168,398				$	123,670
	[1] $39.6 million of the long-term assets in Canada represents goodwill from the acquisition of Tm Bioscience.
	[2] $2.3 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.
	[3] $2.7 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.
	The Company's aggregate foreign currency transaction losses of $385,000 and $215,000 were included in determining the consolidated results for the years ended December 31, 2013 and 2012, respectively.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 20 - RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued guidance on disclosures of additional information with respect to changes in accumulated other comprehensive income ("AOCI") balances by component and significant items reclassified out of AOCI. Expanded disclosures for presentation of changes in AOCI involve disaggregating the total change of each component of other comprehensive income as well as presenting separately for each such component the portion of the change in AOCI related to (1) amounts reclassified into income and (2) current-period other comprehensive income. Additionally, for amounts reclassified into income, disclosure in one location would be required, based upon each specific AOCI component, of the amounts impacting individual income statement line items. Disclosure of the income statement line item impacts will be required only for components of AOCI reclassified into income in their entirety. The disclosures required with respect to income statement line item impacts would be made in either the notes to the consolidated financial statements or parenthetically on the face of the financial statements. For the Company, this Accounting Standards Update is effective beginning January 1, 2013. Because this standard only impacts presentation and disclosure requirements, its adoption did not have a material impact on the Company's consolidated results of operations or financial condition.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance requires an entity to present unrecognized tax benefits as a reduction to deferred tax assets when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. For the Company, this Accounting Standards Update is effective for fiscal years beginning on or after December 15, 2013, and for interim periods within those fiscal years. This pronouncement will have no effect on the financial statements as the Company has historically presented uncertain tax positions in accordance with this Accounting Standards Update.

SELECTED_QUARTERLY_RESULTS_UNA

SELECTED QUARTERLY RESULTS (UNAUDITED)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	NOTE 21 - SELECTED QUARTERLY RESULTS (UNAUDITED)
	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data):
		Quarter Ended
		March 31,			June 30,		September 30,			December 31,
		2013			2013		2013			2013
	Revenue	$	53,200		$	54,287	$	50,780		$	55,156
	Gross profit	37,957			38,057		30,781			36,831
	Income (loss) from operations	(1,552		)	5,041		(4,194		)	5,472
	Net income (loss)	(2,511		)	3,695		796			5,116
	Basic income (loss) per common share	(0.06		)	0.09		0.02			0.12
	Diluted income (loss) per common share	(0.06		)	0.09		0.02			0.12
		Quarter Ended
		March 31,			June 30,		September 30,			December 31,
		2012			2012		2012			2012
	Revenue	$	48,727		$	48,273	$	50,047		$	55,535
	Gross profit	33,760			34,412		35,045			39,357
	Income from operations	5,608			6,486		3,367			7,255
	Net income	3,527			2,952		1,676			4,252
	Basic income per common share	0.09			0.07		0.04			0.1
	Diluted income per common share	0.08			0.07		0.04			0.1

DESCRIPTION_OF_BUSINESS_AND_SU1

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Description of Business	'
	Description of Business
	Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries.  The Company’s xMAP technology, an open architecture, multiplexing technology, allows the Luminex systems to simultaneously perform up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, LEDs, digital signal processors and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. The Company’s xMAP technology is currently being used within various segments of the life sciences industry which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research.  In addition to the Company's xMAP technology, its other offerings include its proprietary MultiCode technology, used for real-time PCR and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.
	The acquisition of GenturaDx was completed on July 11, 2012; therefore the results of operations of GenturaDx in the Company’s consolidated financial statements only include GenturaDx’s results since that date. The acquisition of LMA was completed on June 27, 2011; therefore the results of operations of LMA in the Company’s consolidated financial statements only include LMA's results since that date.
	The Company reclassified certain 2012 amounts in the accompanying consolidated financial statements to conform to the 2013 presentation. These reclassifications include $2.1 million and $2.0 million of ARP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment research and development expenses for the year ended December 31, 2012 and 2011, respectively. Additionally, $12.7 million and $12.4 million of TSP segment selling, general and administrative expenses and the related headcount reclassified to ARP segment selling, general and administrative expenses for the year ended December 31, 2012 and 2011, respectively. These reclassifications had no effect on the Company's consolidated comprehensive income or stockholders' equity.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.
Investments	'
	Investments
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.  Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings.  Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates fair value of these investments.   Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity.  Marketable securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date.  The fair value of all securities is determined by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value.  Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The fair values of financial instruments are determined by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, cost-method investments, long-term investments, accounts payable, accrued liabilities, and long-term debt.  Except for the fair value of the Company’s long-term debt, the fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2013 and 2012. See Note 7 for further details concerning fair value measurements and Note 14 for further details concerning the fair value of the Company’s long-term debt.
Supplemental Cash Flow Statement Information	'
	Supplemental Cash Flow Statement Information (in thousands)
		Year Ended December 31,
		2013			2012			2011
	Cash paid during the period for taxes	$	1,284		$	761		$	1,520
	Cash paid during the period for interest and penalties	124			171			176
	Effect of acquisitions:
	Fair value of tangible assets acquired	—			1,682			6,048
	Liabilities assumed	—			(1,954		)	(164		)
	Cost in excess of fair value of assets acquired	—			8,292			532
	Acquired identifiable intangible assets	—			—			19,681
	Deferred tax assets (liabilities), net	—			2,526			7,617
	In-process research and development	—			40,100			286
		—			50,646			34,000
	Less accrued contingent consideration	—			1,370			—
	Less cash and cash equivalents acquired	—			1,077			86
	Net cash paid for business acquisition	$	—		$	48,199		$	33,914
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company’s short-term investments consist of investments in high credit quality financial institutions, non-government sponsored debt securities and corporate issuers.
	The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses and does not require collateral.
	Thermo Fisher Scientific, Inc., including One Lambda, Inc. acquired in 2012, accounted for 27%, 28% and 33% of the Company’s total TSP segment revenues in 2013, 2012 and 2011, respectively. Bio-Rad Laboratories, Inc. accounted for 15%, 14% and 14% of the Company’s total TSP segment revenues in 2013, 2012 and 2011, respectively.  EMD Millipore accounted for 11%, 13% and 11% of the Company's total TSP segment revenues in 2013, 2012, and 2011, respectively.  LabCorp, including acquired Genzyme Genetics, accounted for 44%, 45%, and 31% of the Company's total ARP segment revenues in 2013, 2012 and 2011, respectively.  Thermo Fisher Scientific, Inc. accounted for 0%, 18% and 24% of the Company’s total ARP segment revenues in 2013, 2012 and 2011, respectively.  Abbott Laboratories accounted for 2%, 9% and 10% of the Company’s total ARP segment revenues in 2013, 2012 and 2011, respectively.  No other customer accounted for more than 10% of total segment revenues in 2013, 2012 or 2011.
Inventories	'
	Inventories
	Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company's markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company's policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company's assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company's estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be overvalued, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company's operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.
Property and Equipment	'
	Property and Equipment
	Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment.  The Company classifies the carrying value of Luminex xMAP Instruments placed within the reagent rental program and the instruments on loan to customers in property and equipment as "Assets on loan/rental."
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Goodwill represents the excess of the cost over the fair value of the assets of the acquired business.  In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, on a reporting unit level.  All of the Company's goodwill relates to one reporting unit, our ARP segment, for goodwill impairment testing.  The Company has historically estimated the fair value of our ARP segment reporting unit using a discounted cash flow (DCF) analysis (“step one” analysis) of the Company’s projected future results.  The step one analysis performed by management in the fourth quarter of 2010 indicated the fair value the ARP segment reporting unit was significantly higher than the carrying value. In 2012 and 2011, the Company applies the accounting guidance which allows an entity to first assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount (“step zero” analysis). In performing the impairment test in the fourth quarter of 2013, the Company used the "step one" analysis. This analysis requires a comparison of the carrying value of the reporting unit to the estimated fair value of the reporting unit.  Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions. The Company's annual test did not result in an impairment charge in 2013 as the estimated fair value of the ARP segment reporting unit continues to exceed the carrying value by a significant enough amount that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit as determined under our "step one" analysis. No goodwill impairments were recorded in 2013, 2012 or 2011.
	The Company utilizes the income approach based on a DCF analysis to determine fair value estimates, and then uses market comparisons as a reasonability check to ensure that neither the income approach nor the market comparisons yielded significantly different results. The income approach calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value using a risk-adjusted discount rate.  The Company's estimates are based on revenue projections by product line, and include judgment based on historical growth and scheduled product approvals by the various governmental authorities.  The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The most significant assumptions used in the DCF methodology are the discount rate, based upon the estimated weighted average cost of capital (WACC), and the terminal growth rate, based upon strategic studies the Company commissioned and the Company's internal analysis.  The Company used the following rates in 2013:
	Assumptions		2013
	WACC		15	%
	Terminal Growth Rate		2.9	%
	To determine the Company's WACC rate, management performed a peer company analysis and considered the weighted average return on debt and equity, the updated risk-free interest rate, beta, equity risk premium, and entity specific size risk premium.  The Company's analysis yielded an estimated fair value in excess of the carrying value by over 25% for 2013.
	Concurrent with the above analysis, management performed a sensitivity analysis based upon reasonably likely changes to determine if the DCF analysis would result in impairment if the following changes were made to management's assumptions:  i) assumed the fair value of the reporting unit was lower by 10% or ii) future revenue was 75% of the Company's projections in the DCF model.  Neither of these sensitivity analyses resulted in an estimated fair value less than the carrying amount of the reporting unit.
	Intangible assets are amortized on a straight line basis over their respective estimated useful lives ranging from 5 to 15 years. As a result of the acquisition of GenturaDx in July 2012, the Company acquired in process research and development of $40.1 million.  In-process research and development will be an indefinite-lived intangible asset until completion or abandonment at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.
Revenue Recognition and Allowance for Doubtful Accounts	'
	Revenue Recognition and Allowance for Doubtful Accounts
	Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company's systems.  The Company recognizes product revenue at the time the product is shipped provided there is persuasive evidence of an agreement, no right of return exists, the fee is fixed or determinable and collectability is probable.  There is no customer right of return in the Company’s sales agreements.  If the criteria for revenue recognition are not met at the time of shipment, the revenue is deferred until all criteria are met.
	The Company regularly enters into arrangements for system sales that are multiple-element arrangements, including services such as installation and training, and multiple products.   These products or services are primarily delivered within a short time frame, approximately three to six months, of the agreement execution date and can also be performed by one of the Company’s third-party partners.  Based on the terms and conditions of the sale, management believes that these services can be accounted for separately from the delivered system as the delivered products have value to customers on a stand-alone basis.  Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis.   Accordingly, the estimated selling price of services or products not yet performed or delivered at the time of system shipment are deferred and recognized as revenue as such services are performed.  The Company has typically been able to determine the selling price of each deliverable in a multiple-element arrangement based on the price for such deliverable when it is sold separately.  If vendor specific objective evidence (VSOE) is not determinable and when third-party evidence is not available, management uses the estimated selling price of a deliverable which is determined based upon the Company’s pricing policies, expected margin of the deliverable, geographical location and information gathered from customer negotiations.
	Within the diagnostic portion of the ARP segment, the Company provides systems and certain other hardware to customers through reagent rental agreements under which the customers commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for diagnostic assays and other disposables. Revenue is recognized over the defined contract term as assays and other disposable products are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred.
	Revenue from extended service agreements is deferred and recognized ratably over the term of the agreement.  The Company may also be entitled to milestone payments that are contingent upon achieving a predefined objective. The Company follows the milestone method of recognizing revenue from milestones and milestone payments are recorded as revenue in full upon achievement of the milestone. Revenues from royalties related to agreements with strategic partners are recognized when such amounts are reported to the Company; therefore, the underlying end user sales may be related to prior periods.
	Additional revenue is derived from cost-type contracts with the U.S. government. Revenue and profit under cost-plus service contracts is recognized as costs are incurred plus negotiated fees. Fixed fees on cost-plus service contracts are recognized ratably over the contract performance period as services are performed. Contract costs include labor and related employee benefits, subcontracting costs and other direct costs, as well as allocations of allowable indirect costs. For contract change orders, claims or similar items, judgment is required for estimating the amounts, assessing the potential for realization, and determining whether realization is probable. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known. Reimbursements of certain costs, including certain hardware costs or out-of-pocket expenses are included in revenue with corresponding costs included in cost of revenue as costs are incurred.
	The Company continuously monitors collections and payments from its customers and maintains allowances for doubtful accounts based upon its historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the Company’s expectations, there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment, in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.
Product-Related Expenses	'
	Product-Related Expenses
	The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.  Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred.  The Company does not have any direct-response advertising.   Advertising expenses, which include trade shows and conventions, were approximately $2.6 million, $2.4 million and $3.1 million for 2013, 2012 and 2011, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Operations.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs are generally expensed in the period incurred.  Nonrefundable advance payments for research and development activities for materials, equipment, facilities, and purchased intangible assets that have an alternative future use are deferred and capitalized.  The capitalized amounts are expensed as the related goods are delivered or the services are performed.  In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses.  These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from 1 to 2 years.
Foreign Currency Translation	'
	Foreign Currency Translation
	The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters”. The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.
Incentive Compensation	'
	Incentive Compensation
	Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date.  A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized.
	The Company recognizes excess tax benefits associated with share-based compensation to stockholders’ equity only when realized. When assessing whether excess tax benefits relating to share-based compensation have been realized, the Company follows the with-and-without approach excluding any indirect effects of the excess tax deductions. Under this approach, excess tax benefits related to share-based compensation are not deemed to be realized until after the utilization of all other tax benefits available to the Company.
	The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes” which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.
Earnings Per Share	'
	Earnings Per Share
	Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718).  ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
Segment Reporting	'
	Segment Reporting
	Management has determined that the Company has two segments for financial reporting purposes:  the TSP segment and the ARP segment.  See Note 19 – Segment and Geographic Information.

DESCRIPTION_OF_BUSINESS_AND_SU2

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Supplemental Cash Flow Statement Information	'
	Supplemental Cash Flow Statement Information (in thousands)
		Year Ended December 31,
		2013			2012			2011
	Cash paid during the period for taxes	$	1,284		$	761		$	1,520
	Cash paid during the period for interest and penalties	124			171			176
	Effect of acquisitions:
	Fair value of tangible assets acquired	—			1,682			6,048
	Liabilities assumed	—			(1,954		)	(164		)
	Cost in excess of fair value of assets acquired	—			8,292			532
	Acquired identifiable intangible assets	—			—			19,681
	Deferred tax assets (liabilities), net	—			2,526			7,617
	In-process research and development	—			40,100			286
		—			50,646			34,000
	Less accrued contingent consideration	—			1,370			—
	Less cash and cash equivalents acquired	—			1,077			86
	Net cash paid for business acquisition	$	—		$	48,199		$	33,914
Rates used for Goodwill Analysis [Table Text Block]	'
	The Company used the following rates in 2013:
	Assumptions		2013
	WACC		15	%
	Terminal Growth Rate		2.9	%

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	12 Months Ended
	Dec. 31, 2013
RESTRUCTURING [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	Statement of Comprehensive Income	2013 Restructuring Plan
	Non-cash impairment charges:
	Inventory	$	2,326
	Property and equipment	1,110
	Intangible Assets	700
	Employee separation costs	783
	Facility exit costs	—
	Other	50
	Total charges	$	4,969
	Recorded to cost of revenue	2,551
	Recorded to restructuring costs	$	2,418
	Rollforward of Accrued Restructuring
	Total charges	$	4,969
	Non-cash impairment charges	(4,136		)
	Employee separation payments	(655		)
	Facility exit costs	—
	Foreign exchange and other adjustments	(50		)
	Balance at December 31, 2013	$	128
	The remaining restructuring accrual balance is expected to be paid within the next six months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of December 31, 2013.

BUSINESS_COMBINATIONS_Tables

BUSINESS COMBINATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Business Acquisition [Line Items]	'
Components of cash purchase price	'
	The purchase price consideration is as follows (in thousands):
	Cash	$	49,276
	Contingent consideration	1,370
	Total purchase price	$	50,646
Summary of estimated fair values of assets acquired and liabilities assumed, acquisition date	'
	The following table summarizes the estimated fair values of GenturaDx’s assets acquired and liabilities assumed at the acquisition date (in thousands):
	Net tangible liabilities assumed as of July 11, 2012	$	(272	)
	Intangible assets subject to amortization	40,100
	Deferred tax assets, net	2,526
	Goodwill	8,292
	Total purchase price	$	50,646
Pro forma financials	'
	In addition, the unaudited pro forma financial information is not intended to be a projection of future results and does not reflect any operating efficiencies or cost savings that might be achievable.
		Year Ended December 31,
		2012			2011
		(unaudited, in thousands except per share data)
	Revenue	$	202,582		$	184,339
	Income from operations	16,276			10,224
	Net income	9,118			5,194
	Net income per common share, basic	$	0.22		$	0.13
	Shares used in computing net income per common share, basic	40,927			41,262
	Net income per common share, diluted	$	0.22		$	0.12
	Shares used in computing net income per common share, diluted	41,884			42,537
Purchase price allocation	'
	The following table summarizes the estimated fair values of LMA’s assets acquired and liabilities assumed at the acquisition date (in thousands):
	Net tangible assets assumed as of June 27, 2011	$	5,884
	Intangible assets subject to amortization	19,967
	Deferred tax assets, net	7,617
	Goodwill	532
	Total purchase price	$	34,000

INVESTMENTS_Tables

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Investments [Abstract]	'
Components of available-for-sale securities	'
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income (Loss)		Losses in Accumulated Other Comprehensive Income (Loss)		Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—	$	46,422
	Non-government sponsored debt securities	4,517		—		—		4,517
	Total current securities	50,939		—		—		50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,939	$	—	$	—	$	50,939
	Available-for-sale securities consisted of the following as of December 31, 2012 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income (Loss)		Losses in Accumulated Other Comprehensive Income (Loss)		Estimated Fair Value
	Current:
	Money Market funds	$	16,987	$	—	$	—	$	16,987
	Non-government sponsored debt securities	13,602		5		—		13,607
	Total current securities	30,589		5		—		30,594
	Noncurrent:
	Non-government sponsored debt securities	3,000		—		—		3,000
	Total noncurrent securities	3,000		—		—		3,000
	Total available-for-sale securities	$	33,589	$	5	$	—	$	33,594
Estimated fair value of available-for-sale debt securities, by contractual maturity	'
	The estimated fair value of available-for-sale debt securities at December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
	Due in one year or less	$	4,517
	Due after one year through two years	—
		$	4,517

ACCOUNTS_RECEIVABLE_AND_RESERV1

ACCOUNTS RECEIVABLE AND RESERVES (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Components of Accounts Receivable	'
	Accounts receivable consisted of the following at December 31 (in thousands):
		2013			2012
	Accounts receivable	$	35,527		$	33,717
	Less: Allowance for doubtful accounts	(4,579		)	(444		)
		$	30,948		$	33,273
Changes in Allowance for Doubtful Accounts	'
	The following table summarizes the changes in the allowance for doubtful accounts (in thousands):
	Balance at December 31, 2010	$	298
	Recoveries charged to costs and expenses	(168		)
	Write-offs of uncollectible accounts	(13		)
	Balance at December 31, 2011	$	117
	Increases charged to costs and expenses	335
	Write-offs of uncollectible accounts	(8		)
	Balance at December 31, 2012	$	444
	Increases charged to costs and expenses	4,604
	Write-offs of uncollectible accounts	(469		)
	Balance at December 31, 2013	$	4,579

INVENTORY_NET_Tables

INVENTORY, NET (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory, Net [Abstract]	'
Inventory	'
	Inventories consisted of the following at December 31 (in thousands):
		2013		2012
	Parts and supplies	$	19,002	$	18,259
	Work-in-progress	4,747		4,831
	Finished goods	6,738		6,847
		$	30,487	$	29,937

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 (in thousands):
		Fair Value Measurements at December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	46,422		$	—	$	—	$	46,422
	Non-government sponsored debt securities	—			4,517		—		4,517
	Liabilities:
	Contingent consideration	—			—		—		—
		Fair Value Measurements at December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets:
	Money Market funds	$	16,987		$	—	$	—	$	16,987
	Non-government sponsored debt securities	—			16,607		—		16,607
	Liabilities:
	Contingent consideration	—			—		1,370		1,370
Schedule Of Reconciliation Of Asset Or Liability Measured At Fair Value On Recurring Basis Significant Unobservable Inputs Level Three [Table Text Block]	'
	Changes in the recurring fair value measurements of financial assets and liabilities using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012 were as follows:
		2013			2012
	Beginning balance	$	1,370		$	—
	Contingent consideration recorded at acquisition	—			1,370
	Fair value adjustments	(1,370		)	—
	Ending balance	$	—		$	1,370

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property and equipment consisted of the following at December 31 (in thousands):
		2013			2012
	Laboratory equipment	$	27,519		$	21,155
	Leasehold improvements	22,881			16,885
	Computer equipment	7,415			7,068
	Purchased software	18,843			15,756
	Furniture and fixtures	4,903			4,834
	Assets on loan/rental	4,027			3,499
	Capital lease equipment	116			116
		85,704			69,313
	Less: Accumulated amortization and depreciation	(52,911		)	(43,084		)
		$	32,793		$	26,229

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	The changes in the carrying amount of goodwill during the period are as follows (in thousands):
		2013			2012
	Balance at beginning of year	$	51,128		$	42,763
	Acquisition of GenturaDx	—			8,292
	Foreign currency translation adjustments	(390		)	73
	Balance at end of year	$	50,738		$	51,128
Schedule of intangible assets	'
	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2012
	Balance at December 31, 2011	$	30,000		$	7,981		$	1,933		$	631		$	40,545
	Additions due to acquisition of GenturaDX	—			—			—			40,100			40,100
	Write-off of  IP R&D projects	—			—			—			(118		)	(118		)
	Foreign currency translation adjustments	30			5			8			14			57
	Balance at December 31, 2012	30,030			7,986			1,941			40,627			80,584
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2011	(9,999		)	(768		)	(341		)	—			(11,108		)
	Amortization expense	(3,187		)	(790		)	(266		)	—			(4,243		)
	Foreign currency translation adjustments	(7		)	(2		)	(6		)	—			(15		)
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Net balance at December 31, 2012	$	16,837		$	6,426		$	1,328		$	40,627		$	65,218
	Weighted average life (in years)	10			11			9
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off/Impairment	(214		)	(7		)	(20		)	(454		)	(695		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	29,676			7,952			1,880			40,100			79,608
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
Estimated aggregate amortization expense for the next five years and thereafter	'
	The estimated aggregate amortization expense for the next five years and thereafter is as follows (in thousands):
	2014	$	3,917
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,848
		20,195
	IPR&D	40,100
		$	60,295

OTHER_COMPREHENSIVE_LOSS_INCOM1

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	12 Months Ended
	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The following table presents the changes in each component of accumulated other comprehensive (loss) income, net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2012	$	1,100		$	1		$	1,101
	Other comprehensive (loss) income before reclassifications	(681		)	11			(670		)
	Amounts reclassified from accumulated other comprehensive income	—			(12		)	(12		)
	Net current-period other comprehensive loss	(681		)	(1		)	(682		)
	Ending balance, December 31, 2013	$	419		$	—		$	419
Comprehensive Income (Loss) [Table Text Block]	'
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive (loss) income (in thousands):
		Twelve Months Ended December 31, 2013
		Before Tax			Tax Benefit			Net of Tax
	Foreign currency translation adjustments	$	(681	)	$	—		$	(681	)
	Unrealized (losses) gains on available-for-sale investments	(2		)	1			(1		)
	Other comprehensive (loss) income	$	(683	)	$	1		$	(682	)

OTHER_ASSETS_Tables

OTHER ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Other Assets [Abstract]	'
Components of Other Assets	'
	Other assets consisted of the following at December 31 (in thousands):
		2013			2012
	Purchased technology rights (net of accumulated amortization of $3,965 and $2,390 in 2013 and 2012, respectively)	$	2,943		$	3,765
	Cost-method investments	1,000			5,081
	Other	959			556
		4,902			9,402
	Less: Current portion	(965		)	(939		)
		$	3,937		$	8,463

ACCRUED_WARRANTY_COSTS_Tables

ACCRUED WARRANTY COSTS (Tables)	12 Months Ended
	Dec. 31, 2013
Product Warranties Disclosures [Abstract]	'
Changes in warranty accrual	'
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2010	$	477
	Warranty expenses	(1,131		)
	Accrual for warranty costs	1,335
	Accrued warranty costs at December 31, 2011	681
	Warranty expenses	(1,119		)
	Accrual for warranty costs	1,041
	Accrued warranty costs at December 31, 2012	603
	Warranty expenses	(1,150		)
	Accrual for warranty costs	1,268
	Accrued warranty costs at December 31, 2013	$	721

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of income before income taxes	'
	The components of income before income taxes for the years ended December 31 are as follows (in thousands):
		2013				2012				2011
	Domestic	$	20,301			$	28,241			$	26,373
	Foreign	(8,877		)		(5,461		)		(2,444		)
	Total	$	11,424			$	22,780			$	23,929
Components of the provision (benefit) for income taxes attributable to continuing operations	'
	The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands):
		2013				2012				2011
	Current:
	Federal	$	4,024			$	4,158			$	8,630
	Foreign	406				(129		)		494
	State	720				928				1,420
	Total current	$	5,150			$	4,957			$	10,544
	Deferred:
	Federal	(381		)		3,945				(604		)
	Foreign	(1		)		1,179				(207		)
	State	(440		)		292				(278		)
	Total deferred	(822		)		5,416				(1,089		)
	Total provision for income taxes	$	4,328			$	10,373			$	9,455
Income tax rate reconciliation	'
	The provision for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages):
		Year Ended December 31,
		2013			2012			2011
	Statutory tax rate	35	%		35	%		35	%
	State taxes, net of federal benefit	0.3	%		3.9	%		2.7	%
	Permanent items	(4.6	)%		2	%		5.3	%
	Effect of foreign operations	3.1	%		0.5	%		(0.4	)%
	Research and incentive tax credit generated	(43.0	)%		(7.1	)%		(2.5	)%
	Valuation allowance	42.6	%		11.6	%		(1.3	)%
	Income tax reserves	4.9	%		0.1	%		0.5	%
	Other	(0.4	)%		(0.5	)%		0.2	%
		37.9	%		45.5	%		39.5	%
Deferred tax assets and liabilities	'
		2013				2012				2011
	Deferred tax assets:
	Current deferred tax assets
	Accrued liabilities and other	$	7,114			$	6,082			$	6,830
	Deferred revenue	1,820				—				—
	Gross current deferred tax assets	8,934				6,082				6,830
	Valuation allowance	(792		)		(536		)		(839		)
	Net current deferred tax assets	8,142				5,546				5,991
	Noncurrent deferred tax assets
	Net operating loss and credit carryforwards	68,973				67,018				48,633
	Deferred revenue	927				2,729				2,867
	Depreciation and amortization	7,899				8,370				7,568
	Stock compensation	4,871				5,851				5,904
	Gross noncurrent deferred tax assets	82,670				83,968				64,972
	Valuation allowance	(49,294		)		(44,132		)		(39,229		)
	Net noncurrent deferred tax assets	$	33,376			$	39,836			$	25,743
	Deferred tax liabilities:
	Current deferred tax liabilities
	Accrued liabilities and other	$	(877	)		$	(763	)		$	—
	Total current deferred tax liabilities	(877		)		(763		)		—
	Net current deferred tax asset	7,265				4,783				5,991
	Noncurrent deferred tax liabilities
	Depreciation and amortization	(19,788		)		(22,784		)		(9,352		)
	Stock compensation	(53		)		(61		)		(92		)
	Acquired intangibles	(1,622		)		(2,631		)		(3,482		)
	Total noncurrent deferred tax liabilities	(21,463		)		(25,476		)		(12,926		)
	Net noncurrent deferred tax asset	11,913				14,360				12,817
	Net deferred tax assets	$	19,178			$	19,143			$	18,808
Reconciliation of unrecognized tax benefits	'
	A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):
		2013				2012
	Balance at beginning of year	$	1,760			$	1,370
	Additions based on tax positions related to the current year	335				390
	Additions for tax positions of prior years	238				—
	Reductions for tax positions of prior years	—				—
	Settlements	—				—
	Lapse of statute of limitations	—				—
	Cumulative translation adjustment	—				—
	Balance at end of year	$	2,333			$	1,760

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of estimated debt repayment for the next five years and thereafter	'
	Estimated repayments on the debt for the next five years and thereafter are as follows (in thousands):
	2014	$	1,194
	2015	469
	2016	—
	2017	—
	2018	—
	Thereafter	—
		$	1,663
	Less: Amount representing implied interest	(6		)
	Total principal repayments	$	1,657
	Discount	—
	Total long-term debt	$	1,657
	Less: Current portion of long-term debt	(1,194		)
		$	463

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	The following table sets forth the computation of basic and diluted net income per share (in thousands, except share and per share data):
		Year Ended December 31,
		2013		2012		2011
	Numerator:
	Net income	$	7,096	$	12,407	$	14,474
	Denominator:
	Denominator for basic net income per share - weighted average common stock outstanding	40,799		40,927		41,262
	Effect of dilutive securities:
	Stock options and awards	1,187		957		1,275
	Denominator for diluted net income per share - weighted average shares outstanding - diluted	41,986		41,884		42,537
	Basic net income per share	$	0.17	$	0.3	$	0.35
	Diluted net income per share	$	0.17	$	0.3	$	0.34

STOCKHOLDERS_EQUITY_EMPLOYEE_B1

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule Of Assumptions For Employee Stock Purchase Plan [Line Items]	'
Fair value assumptions used for stock-based compensation costs	'
	The assumptions used are summarized in the following table:
		2013				2012				2011
	Dividend yield	—		%		—		%		—		%
	Expected volatility	0.5				0.5				0.5
	Risk-free rate of return	1.2		%		1.2		%		2.3		%
	Expected life	7 years				7 years				7 years
	Weighted average fair value at grant date	$	8.79			$	7.78			$	7.67
Stock options activity	'
	The Company’s stock option activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
	Stock Options	Shares			Weighted Average Exercise Price				Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
		(in thousands)
	Outstanding at December 31, 2010	2,367			$	10.82
	Granted	84			18.26
	Exercised	(304	)		11.65
	Cancelled or expired	(127	)		23.74
	Outstanding at December 31, 2011	2,020			$	10.19
	Granted	160			22.53
	Exercised	(487	)		7.22
	Cancelled or expired	(17	)		20.37
	Outstanding at December 31, 2012	1,676			$	12.13
	Granted	159			17.24
	Exercised	(835	)		9.06
	Cancelled or expired	(33	)		19.8
	Outstanding at December 31, 2013	967			$	15.35			4.65		$	4,417
	Vested at December 31, 2013 and expected to vest	965			$	15.34			4.64		$	4,413
	Exercisable at December 31, 2013	701			$	13.91			3.14		$	4,066
Restricted shares activity	'
	The Company’s restricted share activity for the years ended December 31, 2011, 2012 and 2013 is as follows:
	Restricted Stock Awards	Shares			Weighted Average Grant Price
		(in thousands)
	Non-vested at December 31, 2010	1,093			$	16.41
	Granted	239			18.73
	Vested	(362	)		16.11
	Cancelled or expired	(67	)		16.57
	Non-vested at December 31, 2011	903			$	17.13
	Granted	329			22.5
	Vested	(339	)		16.75
	Cancelled or expired	(75	)		18.59
	Non-vested at December 31, 2012	818			$	19.32
	Granted	354			17.28
	Vested	(267	)		18.83
	Cancelled or expired	(79	)		19.15
	Non-vested at December 31, 2013	826			$	18.62
	Restricted Stock Units	Shares			Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
		(in thousands)
	Non-vested at December 31, 2010	768
	Granted	269
	Vested	(58	)
	Cancelled or expired	(152	)
	Non-vested at December 31, 2011	827
	Granted	246
	Vested	(80	)
	Cancelled or expired	(118	)
	Non-vested at December 31, 2012	875
	Granted	199
	Vested	(79	)
	Cancelled or expired	(162	)
	Non-vested at December 31, 2013	833			1.82		$	16,167
	Vested at December 31, 2013 and expected to vest	578			1.81		$	10,439
	Exercisable at December 31, 2013	40			0		$	766
Stock-based compensation costs recognized in consolidated statements of income	'
	The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands):
		Year Ended December 31,
		2013				2012				2011
	Cost of revenue	$	856			$	947			$	917
	Research and development	2,553				2,034				2,126
	Selling, general and administrative	5,812				6,934				8,374
	Stock-based compensation costs reflected in net income	$	9,221			$	9,915			$	11,417
Reserved shares by plan	'
	The following table summarizes the reserved shares by plan as of December 31, 2013:
		Options Outstanding			Shares Available for Future Issuance			Total Shares Reserved
	2000 Plan	97,000			—			97,000
	2001 Plan	27,060			—			27,060
	2006 Equity Incentive Plan	1,715,876			3,882,275			5,598,151
	ESPP Plan	—			393,478			393,478
	Balthrop Option	200,000			—			200,000
		2,039,936			4,275,753			6,315,689
Employee Stock Purchase Plan [Member]	'
Schedule Of Assumptions For Employee Stock Purchase Plan [Line Items]	'
Fair value assumptions used for stock-based compensation costs	'
	The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions:
		2013
	Assumptions:
	Risk-free interest rates	.09% to 0.15%
	Expected life	0.5 years
	Expected volatility	0.51
	Dividend yield	—	%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Summary of minimum lease commitments for the next five years	'
	Minimum annual lease commitments as of December 31, 2013 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands):
	2014	$	4,120
	2015	2,785
	2016	1,811
	2017	1,498
	2018	1,310
	Thereafter	5,516
	Total	$	17,040

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
	Following is selected information for the years ended December 31, 2013 and 2012 or as of December 31, 2013 and 2012 (in thousands):
		2013							2012
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment				Consolidated
	Revenues from external customers	$	132,023	$	81,400		$	213,423	$	121,032	$	81,550			$	202,582
	Depreciation and amortization	7,990		7,932			15,922		6,930		7,434				14,364
	Operating profit (loss)	33,761		(28,994		)	4,767		27,829		(5,113		)		22,716
	Segment assets	154,174		151,872			306,046		140,896		156,279				297,175
Schedule of sales and long-term assets by geographical area	'
	The table below provides information regarding long-term assets and product revenues from the Company’s sales to customers within the United States and in foreign countries for the years ended December 31 (in thousands):
		Sales to Customers							Long-Term Assets
		2013		2012			2011		2013				2012					2011
	Domestic	$	178,276	$	167,924		$	152,480	$	109,448			$	113,700				$	66,094
	Foreign:
	Europe	16,690		17,376			16,029		1,012				1,433					978
	Asia	12,287		10,877			9,481		234				212					280
	Canada	3,025		3,753			2,892		46,535		[1]		48,929				[1]	52,028		[1]
	Australia	1,299		963			1,344		2,443		[2]		4,108				[3]	4,252		[3]
	Other	1,846		1,689			2,113		4				16					38
		$	213,423	$	202,582		$	184,339	$	159,676			$	168,398				$	123,670
	[1] $39.6 million of the long-term assets in Canada represents goodwill from the acquisition of Tm Bioscience.
	[2] $2.3 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.
	[3] $2.7 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.

SELECTED_QUARTERLY_RESULTS_Tab

SELECTED QUARTERLY RESULTS (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data):
		Quarter Ended
		March 31,			June 30,		September 30,			December 31,
		2013			2013		2013			2013
	Revenue	$	53,200		$	54,287	$	50,780		$	55,156
	Gross profit	37,957			38,057		30,781			36,831
	Income (loss) from operations	(1,552		)	5,041		(4,194		)	5,472
	Net income (loss)	(2,511		)	3,695		796			5,116
	Basic income (loss) per common share	(0.06		)	0.09		0.02			0.12
	Diluted income (loss) per common share	(0.06		)	0.09		0.02			0.12
		Quarter Ended
		March 31,			June 30,		September 30,			December 31,
		2012			2012		2012			2012
	Revenue	$	48,727		$	48,273	$	50,047		$	55,535
	Gross profit	33,760			34,412		35,045			39,357
	Income from operations	5,608			6,486		3,367			7,255
	Net income	3,527			2,952		1,676			4,252
	Basic income per common share	0.09			0.07		0.04			0.1
	Diluted income per common share	0.08			0.07		0.04			0.1

DESCRIPTION_OF_BUSINESS_AND_SU3

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Concentration Risk [Line Items]	'	'	'
Fair Value Inputs, Discount Rate	15.00%	'	'
Fair Value Inputs, Long-term Revenue Growth Rate	2.90%	'	'
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	25.00%	'	'
Goodwill sensitivity analysis, adjustment of fair value of reporting unit	10.00%	'	'
Goodwill sensitivity analysis, adjustment of future revenue projections	75.00%	'	'
Supplemental Cash Flow Information [Abstract]	'	'	'
Cash paid during the period for taxes	$1,284,000	$761,000	$1,520,000
Cash paid during the period for interest and penalties	124,000	171,000	176,000
Effect of acquisitions:	'	'	'
Fair value of tangible assets acquired	0	1,682,000	6,048,000
Liabilities assumed	0	-1,954,000	-164,000
Cost in excess of fair value of assets acquired	0	8,292,000	532,000
Acquired identifiable intangible assets	0	0	19,681,000
Deferred tax assets (liabilities), net	0	2,526,000	7,617,000
In-process research and development	0	40,100,000	286,000
Business Acquisition, Purchase Price, Cost of Acquired Entity	0	50,646,000	34,000,000
Less accrued contingent consideration	0	1,370,000	0
Less cash and cash equivalents acquired	0	1,077,000	86,000
Net cash paid for business acquisition	0	48,199,000	33,914,000
Technology and Strategic Partnerships [Member] | Thermo Fisher Scientific, Inc., including acquired One Lambda, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	27.00%	28.00%	33.00%
Technology and Strategic Partnerships [Member] | Bio-Rad Laboratories, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	15.00%	14.00%	14.00%
Technology and Strategic Partnerships [Member] | EMD Millipore [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	11.00%	13.00%	11.00%
Assays and Related Products [Member] | LabCorp, including acquired Genzyme Genetics [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	44.00%	45.00%	31.00%
Assays and Related Products [Member] | Thermo Fisher Scientific, Inc. [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	0.00%	18.00%	24.00%
Assays and Related Products [Member] | Abbott Laboratories [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Percentage of total segment revenues	2.00%	9.00%	10.00%
Research and Development Expense [Member] | Assays and Related Products [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Prior Period Reclassification Adjustment	'	2,100,000	2,000,000
Selling, General and Administrative Expenses [Member] | Assays and Related Products [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Prior Period Reclassification Adjustment	'	$12,700,000	$12,400,000

DESCRIPTION_OF_BUSINESS_AND_SU4

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible Assets [Line Items]	'	'	'
Goodwill, Impairment Loss	$0	$0	$0
In-process research and development	0	40,100,000	286,000
Assets [Abstract]	'	'	'
Advertising expenses	2,600,000	2,400,000	3,100,000
Number of segments for financial reporting purposes	2	'	'
Business Acquisition - GenturaDx (British Virgin Islands) [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
In-process research and development	$40,100,000	'	'
Customer Lists and Contracts [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Intangible assets, estimated lives	'11 years	'11 years	'
Minimum [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Intangible assets, estimated lives	'5 years	'	'
Assets [Abstract]	'	'	'
Property and equipment, Useful Life	'2 years	'	'
Minimum [Member] | Research and Development Expense [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Intangible assets, estimated lives	'1 year	'	'
Maximum [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Intangible assets, estimated lives	'15 years	'	'
Assets [Abstract]	'	'	'
Property and equipment, Useful Life	'7 years	'	'
Maximum [Member] | Research and Development Expense [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Intangible assets, estimated lives	'2 years	'	'

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	$4,136
Employee Separation Costs	783
Facility Exit Costs	0
Other Restructuring Costs	50
Total Restructuring Charges	4,969
Restructuring and Related Cost, Number of Positions Eliminated, Percent	5.00%
Restructuring Charges Included In Cost Of Revenue	2,551
Restructuring Charges And Associated Cost	2,418
Employee Separation Payments	-655
Foreign Exchange and Other Adjustments	-50
Restructuring Reserve	128
Inventories [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	2,326
Property, Plant and Equipment [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	1,110
Intangible assets (restructuring) [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Asset Impairment Charges	$700

BUSINESS_COMBINATIONS_Details

BUSINESS COMBINATIONS (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 11, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Jun. 27, 2011

Jul. 11, 2012

Jul. 11, 2012

Dec. 31, 2012

Share data in Thousands, except Per Share data, unless otherwise specified

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - EraGen Biosciences, Inc. [Member]

Business Acquisition - EraGen Biosciences, Inc. [Member]

Future Development and Regulatory Milestone Dec 2013 [Member]

Future Development and Regulatory Milestone June 2014 [Member]

Customer Lists [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, amount of purchase price deposited in escrow

'

'

'

$8,100,000

'

'

'

'

'

'

'

'

Business acquisition, amount of purchase price remaining in escrow

'

'

'

'

'

'

5,000,000

'

'

'

'

'

Business acquisition, estimated fair values of assets acquired and liabilities assumed [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Net tangible liabilities assumed

'

'

'

-272,000

'

'

'

'

'

'

'

'

Net tangible assets assumed

'

'

'

'

'

'

'

'

5,884,000

'

'

'

Business acquisition, intangible assets subject to amortization

'

'

'

40,100,000

40,100,000

'

40,100,000

'

19,967,000

'

'

0

Business acquisition, deferred tax assets, net

0

2,526,000

7,617,000

2,526,000

'

'

'

'

7,617,000

'

'

'

Business acquisition, goodwill

'

'

'

8,292,000

'

'

'

'

532,000

'

'

'

Total purchase price

0

50,646,000

34,000,000

50,646,000

'

'

50,646,000

'

34,000,000

'

'

'

Cash Flow Projections Discount Rate

'

'

'

29.50%

'

'

'

'

'

'

'

'

Fair value adjustment increasing inventory

'

'

'

'

'

'

'

3,300,000

'

'

'

'

Revenue from date of acquisition

'

'

'

'

0

'

'

7,600,000

'

'

'

'

Operating loss from date of acquisition

'

'

'

'

7,900,000

'

'

4,600,000

'

'

'

'

Pro Forma Financial Information [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Revenue

'

'

'

'

202,582,000

184,339,000

'

'

'

'

'

'

Income from operations

'

'

'

'

16,276,000

10,224,000

'

'

'

'

'

'

Net income

'

'

'

'

9,118,000

5,194,000

'

'

'

'

'

'

Net income per share, basic (in dollars per share)

'

'

'

'

$0.22

$0.13

'

'

'

'

'

'

Shares used in computing net income per share, basic (in shares)

'

'

'

'

40,927

41,262

'

'

'

'

'

'

Net income per share, diluted (in dollars per share)

'

'

'

'

$0.22

$0.12

'

'

'

'

'

'

Shares used in computing net income per share, diluted (in shares)

'

'

'

'

41,884

42,537

'

'

'

'

'

'

Cash consideration

'

'

'

49,276,000

'

'

'

'

'

'

'

'

Contingent consideration

'

'

'

1,370,000

'

'

'

'

'

'

'

'

Acquisition related costs included in selling, general and administrative expense

'

'

'

'

4,300,000

'

'

2,100,000

'

'

'

'

Business Acquisition, Contingent Consideration, Potential Cash Pmt

$0

$1,370,000

$0

'

'

'

'

'

'

$3,000,000

$7,000,000

'

Percentage of milestone payments for indemnification claims

'

'

'

'

'

'

30.00%

'

'

'

'

'

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$50,939,000	$33,589,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	5,000
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	50,939,000	33,594,000
Proceeds from Sale of Available-for-sale Securities	0	6,000,000
Available-for-sale securities, debt maturities [Abstract]	'	'
Due in one year or less	4,517,000	'
Due after one year through two years	0	'
Total estimated fair value of available-for-sale debt securities	4,517,000	'
Money Market Funds [Member]	'	'
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	46,422,000	16,987,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	46,422,000	16,987,000
Current Non-Government Sponsored Debt Securities [Member]	'	'
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	4,517,000	13,602,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	5,000
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	4,517,000	13,607,000
Total Current Available-for-sale Securities [Member]	'	'
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	50,939,000	30,589,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	5,000
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	50,939,000	30,594,000
Non-Current Non-Government Sponsored Debt Securities [Member]	'	'
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	0	3,000,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	0	3,000,000
Total Non-Current Available-for-sale Securities [Member]	'	'
Components of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	0	3,000,000
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	$0	$3,000,000

ACCOUNTS_RECEIVABLE_AND_RESERV2

ACCOUNTS RECEIVABLE AND RESERVES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Receivables [Abstract]	'	'	'
Accounts receivable, gross	$35,527	$33,717	'
Less: Allowance for doubtful accounts	-4,579	-444	'
Accounts receivable, net	30,948	33,273	'
Allowance for Doubtful Accounts [Roll Forward]	'	'	'
Balance	444	117	298
Reductions charged to costs and expenses	4,604	335	-168
Write-offs of uncollectible accounts	-469	-8	-13
Balance	$4,579	$444	$117

INVENTORY_NET_Details

INVENTORY, NET (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory, Net [Abstract]	'	'
Parts and supplies	$19,002,000	$18,259,000
Work-in-progress	4,747,000	4,831,000
Finished goods	6,738,000	6,847,000
Inventory, net	30,487,000	29,937,000
Non-cancelable purchase commitments	$12,100,000	'

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2013	Jul. 11, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified		Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]
				Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 1 [Member]	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Estimate of Fair Value, Fair Value Disclosure [Member]	Estimate of Fair Value, Fair Value Disclosure [Member]
Amounts included in asset accounts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Money Market funds	'	'	'	$46,422	$16,987	$0	$0	$0	$0	$46,422	$16,987
Non-government sponsored debt securities	'	'	'	0	0	4,517	16,607	0	0	4,517	16,607
Amounts included in liability accounts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Contingent consideration	$0	$0	$1,370	$0	$0	$0	$0	$0	$1,370	$0	$1,370

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jul. 11, 2012
In Thousands, unless otherwise specified		Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]	Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Beginning Balance	'	$1,370	$0	'
Contingent Consideration Fair Value	0	0	'	1,370
Fair Value Adjustments	'	-1,370	0	'
Ending Balance	'	$0	$1,370	'

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	$85,704,000	$69,313,000	'
Less: Accumulated amortization and depreciation	-52,911,000	-43,084,000	'
Property, plant and equipment, net	32,793,000	26,229,000	'
Depreciation expense	10,200,000	8,800,000	7,800,000
Laboratory Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	27,519,000	21,155,000	'
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	22,881,000	16,885,000	'
Computer Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	7,415,000	7,068,000	'
Purchased Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	18,843,000	15,756,000	'
Furniture and Fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	4,903,000	4,834,000	'
Assets On Loan/Rental [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	4,027,000	3,499,000	'
Capital Lease Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, plant and equipment, gross	$116,000	$116,000	'

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Jul. 11, 2012

Jun. 27, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - EraGen Biosciences, Inc. [Member]

In-process Research and Development [Member]

In-process Research and Development [Member]

In-process Research and Development [Member]

Customer Lists and Contracts [Member]

Customer Lists and Contracts [Member]

Customer Lists and Contracts [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, goodwill

'

'

'

'

$8,292,000

$532,000

'

'

'

'

'

'

'

'

Business acquisition, other intangible assets

'

'

40,100,000

40,100,000

40,100,000

19,967,000

'

'

40,100,000

'

'

0

'

'

Intangible assets, estimated lives

'

'

'

'

'

'

'

'

'

'11 years

'11 years

'

'5 years

'15 years

Research and Development Expense, Estimated

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

8,000,000

Write-off of IP R&D projects

695,000

118,000

'

'

'

'

454,000

118,000

'

7,000

0

'

'

'

Goodwill [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at beginning of year

51,128,000

42,763,000

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition during period

0

'

8,292,000

'

'

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustments

-390,000

73,000

'

'

'

'

'

'

'

'

'

'

'

'

Balance at end of period

$50,738,000

$51,128,000

'

'

'

'

'

'

'

'

'

'

'

'

GOODWILL_AND_OTHER_INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS (Details 2) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Jul. 11, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

In-process Research and Development [Member]

In-process Research and Development [Member]

In-process Research and Development [Member]

Technology, Trade Secrets, and Know-how [Member]

Technology, Trade Secrets, and Know-how [Member]

Technology, Trade Secrets, and Know-how [Member]

Customer Lists and Contracts [Member]

Customer Lists and Contracts [Member]

Customer Lists and Contracts [Member]

Other Identifiable Intangible Assets [Member]

Other Identifiable Intangible Assets [Member]

Other Identifiable Intangible Assets [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Business Acquisition - GenturaDx (British Virgin Islands) [Member]

Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, beginning

$80,584

$40,545

'

'

'

'

$40,627

$631

'

$30,030

$30,000

'

$7,986

$7,981

'

$1,941

$1,933

'

Business acquisition, intangible assets subject to amortization

'

'

'

40,100

40,100

40,100

'

'

40,100

'

'

0

'

'

0

'

'

0

Write-off of IP R&D projects

-695

-118

'

'

'

'

-454

-118

'

-214

0

'

-7

0

'

-20

0

'

Foreign currency translation adjustments

-281

57

'

'

'

'

-73

14

'

-140

30

'

-27

5

'

-41

8

'

Balance, ending

79,608

80,584

40,545

'

'

'

40,100

40,627

'

29,676

30,030

'

7,952

7,986

'

1,880

1,941

'

Less: accumulated amortization [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated amortization, beginning balance

-15,366

-11,108

'

'

'

'

0

0

'

-13,193

-9,999

'

-1,560

-768

'

-613

-341

'

Amortization expense

-4,099

-4,243

-3,375

'

'

'

0

0

'

-3,172

-3,187

'

-787

-790

'

-140

-266

'

Foreign currency translation adjustments

152

-15

'

'

'

'

0

0

'

93

-7

'

21

-2

'

38

-6

'

Accumulated amortization, ending balance

-19,313

-15,366

-11,108

'

'

'

0

0

'

-16,272

-13,193

'

-2,326

-1,560

'

-715

-613

'

Net balance

60,295

65,218

'

'

'

'

40,100

40,627

'

13,404

16,837

'

5,626

6,426

'

1,165

1,328

'

Weighted average life (in years)

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'11 years

'11 years

'

'9 years

'9 years

'

Estimated aggregate amortization expense for the next five years and thereafter [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

3,917

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

3,232

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

3,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

2,144

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

1,954

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

5,848

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total amortization of finite-lived intangibles

20,195

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

IP R&D

40,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total future amortization expense

$60,295

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

OTHER_COMPREHENSIVE_LOSS_INCOM2

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'
Beginning balance, December 31, 2012	$419	$1,101	'
Other comprehensive (loss) income before reclassifications	-670	'	'
Amounts reclassified from accumulated other comprehensive income	-12	'	'
Net current-period other comprehensive loss	-682	117	-166
Ending balance, December 31, 2013	419	1,101	'
Available-for-sale Securities [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'
Beginning balance, December 31, 2012	0	1	'
Other comprehensive (loss) income before reclassifications	11	'	'
Amounts reclassified from accumulated other comprehensive income	-12	'	'
Net current-period other comprehensive loss	-1	'	'
Ending balance, December 31, 2013	0	1	'
Accumulated Translation Adjustment [Member]	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'
Beginning balance, December 31, 2012	419	1,100	'
Other comprehensive (loss) income before reclassifications	-681	'	'
Amounts reclassified from accumulated other comprehensive income	0	'	'
Net current-period other comprehensive loss	-681	'	'
Ending balance, December 31, 2013	$419	$1,100	'

OTHER_COMPREHENSIVE_LOSS_INCOM3

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'
Foreign currency translation adjustments, before tax	($681)	'	'
Foreign currency translation adjustments, tax benefit	0	'	'
Foreign currency translation adjustments, net of tax	-681	'	'
Unrealized gains on available-for-sale investments, before tax	-2	'	'
Unrealized gains on available-for-sale investments, tax benefit	1	'	'
Unrealized gains on available-for-sale investments, net of tax	-1	'	'
Other Comprehensive (loss) income, before tax	-683	'	'
Other Comprehensive (loss) income, tax benefit	1	'	'
Other Comprehensive (loss) income, net of tax	($682)	$117	($166)

OTHER_ASSETS_Details

OTHER ASSETS (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2012
Other Assets [Abstract]	'	'	'	'
Purchased technology rights (net of accumulated amortization)	'	$2,943,000	$3,765,000	'
Cost-method investments	'	1,000,000	5,081,000	'
Other	'	959,000	556,000	'
Total other assets	'	4,902,000	9,402,000	'
Less: Current portion	'	-965,000	-939,000	'
Non-current other assets	'	3,937,000	8,463,000	'
Accumulated amortization, purchased technology rights	'	3,965,000	2,390,000	'
Amortization expense relating to acquired technology rights	'	1,639,000	1,304,000	'
Significant influence percentage (in hundredths)	'	20.00%	'	'
Amount of investments in a private company	'	'	'	1,000,000
Cost-method Investments, Realized Gain (Loss)	5,400,000	'	'	'
Estimated future amortization expense [Abstract]	'	'	'	'
2014	'	1,345,000	'	'
2015	'	408,000	'	'
2016	'	182,000	'	'
2017	'	161,000	'	'
2018	'	103,000	'	'
Thereafter	'	$744,000	'	'

ACCRUED_WARRANTY_COSTS_Details

ACCRUED WARRANTY COSTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accrued warranty costs [Roll Forward]	'	'	'
Accrued warranty costs	$603	$681	$477
Warranty expenses	-1,150	-1,119	-1,131
Accrual for warranty costs	1,268	1,041	1,335
Accrued warranty costs	$721	$603	$681

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of income tax expense (benefit) [Abstract]	'	'	'
Domestic	$20,301,000	$28,241,000	$26,373,000
Foreign	-8,877,000	-5,461,000	-2,444,000
Income before income taxes	11,424,000	22,780,000	23,929,000
Federal	4,024,000	4,158,000	8,630,000
Foreign	406,000	-129,000	494,000
State	720,000	928,000	1,420,000
Total current	5,150,000	4,957,000	10,544,000
Deferred [Abstract]	'	'	'
Federal	-381,000	3,945,000	-604,000
Foreign	-1,000	1,179,000	-207,000
State	-440,000	292,000	-278,000
Total deferred	-822,000	5,416,000	-1,089,000
Total provision (benefit) for income taxes	4,328,000	10,373,000	9,455,000
Income tax rate reconciliation [Abstract]	'	'	'
Statutory tax rate (in hundredths)	35.00%	35.00%	35.00%
State taxes, net of federal benefit (in hundredths)	0.30%	3.90%	2.70%
Permanent items (in hundredths)	-4.60%	2.00%	5.30%
Effect of foreign operations (in hundredths)	3.10%	0.50%	-0.40%
Research and incentive tax credit generated (in hundredths)	-43.00%	-7.10%	-2.50%
Valuation allowance (in hundredths)	42.60%	11.60%	-1.30%
Income tax reserves (in hundredths)	4.90%	0.10%	0.50%
Other (in hundredths)	-0.40%	-0.50%	0.20%
Effective tax rate, excluding amounts recorded for discrete events (in hundredths)	37.90%	45.50%	39.50%
Current deferred tax assets [Abstract]	'	'	'
Accrued liabilities and other	7,114,000	6,082,000	6,830,000
Deferred Tax Assets, Current, Deferred Income	1,820,000	0	0
Gross current deferred tax assets	8,934,000	6,082,000	6,830,000
Valuation allowance	-792,000	-536,000	-839,000
Net current deferred tax assets	8,142,000	5,546,000	5,991,000
Noncurrent deferred tax assets [Abstract]	'	'	'
Net operating loss and credit carryforwards	68,973,000	67,018,000	48,633,000
Deferred revenue	927,000	2,729,000	2,867,000
Depreciation and amortization	7,899,000	8,370,000	7,568,000
Stock compensation	4,871,000	5,851,000	5,904,000
Gross noncurrent deferred tax assets	82,670,000	83,968,000	64,972,000
Valuation allowance	-49,294,000	-44,132,000	-39,229,000
Net noncurrent deferred tax asset	33,376,000	39,836,000	25,743,000
Current deferred tax liabilities [Abstract]	'	'	'
Accrued liabilities and other	-877,000	-763,000	0
Total current deferred tax liabilities	-877,000	-763,000	0
Net current deferred tax asset	7,265,000	4,783,000	5,991,000
Noncurrent deferred tax liabilities [Abstract]	'	'	'
Depreciation and amortization	-19,788,000	-22,784,000	-9,352,000
Stock Compensation	-53,000	-61,000	-92,000
Acquired intangibles	-1,622,000	-2,631,000	-3,482,000
Total noncurrent deferred tax liabilities	-21,463,000	-25,476,000	-12,926,000
Net noncurrent deferred tax asset	11,913,000	14,360,000	12,817,000
Net deferred tax assets	19,178,000	19,143,000	18,808,000
Valuation Allowance [Line Items]	'	'	'
Increase (Decrease) in valuation allowance	5,400,000	'	'
Federal net operating losses carry-forwards	79,900,000	'	'
Net operating loss carry-forwards, State and local	53,800,000	'	'
Foreign non-capital income tax loss carry-forwards	28,500,000	'	'
Operating Loss Carryforwards, Expiration Dates	31-Dec-15	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	4,900,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	10,900,000	'	'
Tax Credit Carryforward, Expiration Dates	31-Dec-18	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration	4,400,000	'	'
Undistributed earnings of non-U.S. subsidiaries	920,000	1,200,000	2,100,000
Unrecognized tax benefits that would impact effective tax rate	2,300,000	1,800,000	'
Tax related interest and penalties	14,000	14,000	'
Reconciliation of unrecognized tax benefits [Roll Forward]	'	'	'
Balance, Beginning of period	1,760,000	1,370,000	'
Additions based on tax positions related to the current year	335,000	390,000	'
Additions for tax positions of prior years	238,000	0	'
Reductions for tax positions of prior years	0	0	'
Settlements	0	0	'
Lapse of statute of limitations	0	0	'
Cumulative translation adjustment	0	0	'
Balance, End of period	2,333,000	1,760,000	1,370,000
Stock-Based Compensation [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Federal net operating losses carry-forwards	20,100,000	'	'
Domestic Country [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Amount of net operating loss acquired in business acquisition	59,800,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards	10,400,000	'	'
Domestic Country [Member] | Stock-Based Compensation [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards	6,900,000	'	'
Canada [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	57,200,000	'	'
State and Local Jurisdiction [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Amount of net operating loss acquired in business acquisition	53,800,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards	1,800,000	'	'
State and Local Jurisdiction [Member] | Business Acquisition - GenturaDx (British Virgin Islands) [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards	1,100,000	'	'
2012 [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Amount of tax benefit included in income tax provision	664,000	'	'
2013 [Member]	'	'	'
Valuation Allowance [Line Items]	'	'	'
Amount of tax benefit included in income tax provision	$1,300,000	'	'

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details)	12 Months Ended						12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2008	Dec. 31, 2007	Dec. 12, 2003	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	USD ($)	USD ($)			CAD	Technology Partnerhsip Canada [Member]	Technology Partnerhsip Canada [Member]
							USD ($)	CAD
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Proceeds from the TPC loan	'	'	'	'	'	'	$4,500,000	4,900,000
Imputed interest payable	'	'	'	'	'	'	1,500,000	'
Total Due	1,663,000	'	'	'	'	'	6,100,000	6,500,000
Interest and advances repaid	124,000	171,000	176,000	'	'	'	4,400,000	4,700,000
Royalty payments percentage of revenue (in hundredths)	'	'	'	2.50%	1.00%	'	'	'
Technology Partnership Canada debt maturity date	'	'	'	'	'	'	31-Dec-16	31-Dec-16
2014	1,194,000	'	'	'	'	'	'	'
2015	469,000	'	'	'	'	'	'	'
2016	0	'	'	'	'	'	'	'
2017	0	'	'	'	'	'	'	'
2018	0	'	'	'	'	'	'	'
Thereafter	0	'	'	'	'	'	'	'
Total Debt	1,663,000	'	'	'	'	'	6,100,000	6,500,000
Less: Amount representing implied interest	-6,000	'	'	'	'	'	'	'
Total principal repayments	1,657,000	'	'	'	'	'	'	'
Discount	0	'	'	'	'	'	'	'
Total long-term debt	1,657,000	'	'	'	'	'	'	'
Less: Current portion of long-term debt	-1,194,000	-1,138,000	'	'	'	'	'	'
Loan payable to Technology Partnership Canada (TPC)	463,000	1,702,000	'	'	'	7,300,000	'	'
Imputed interest expense related to its long-term debt	48,000	89,000	'	'	'	'	'	'
Effective interest rate (in hundredths)	3.90%	3.90%	'	'	'	'	'	'
Fair value of the Company's long-term debt	$1,500,000	$2,500,000	'	'	'	'	'	'

NET_INCOME_PER_SHARE_Details

NET INCOME PER SHARE (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator:	'	'	'	'	'	'	'	'	'	'	'
Net income	$5,116	$796	$3,695	($2,511)	$4,252	$1,676	$2,952	$3,527	$7,096	$12,407	$14,474
Denominator:	'	'	'	'	'	'	'	'	'	'	'
Denominator for basic net income per share - weighted average common stock outstanding (in shares)	'	'	'	'	'	'	'	'	40,799,000	40,927,000	41,262,000
Effect of dilutive securities [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Stock options and awards (in shares)	'	'	'	'	'	'	'	'	1,187,000	957,000	1,275,000
Denominator for diluted net income per share - weighted average shares outstanding - diluted (in shares)	'	'	'	'	'	'	'	'	41,986,000	41,884,000	42,537,000
Basic net income per share (in dollars per share)	$0.12	$0.02	$0.09	($0.06)	$0.10	$0.04	$0.07	$0.09	$0.17	$0.30	$0.35
Diluted net income per share (in dollars per share)	$0.12	$0.02	$0.09	($0.06)	$0.10	$0.04	$0.07	$0.08	$0.17	$0.30	$0.34
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Anti-dilutive restricted stock awards, stock options	'	'	'	'	'	'	'	'	381,000	364,000	141,000

STOCKHOLDERS_EQUITY_EMPLOYEE_B2

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK BASED COMPENSATION (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Stock Options [Member]

Employee Stock [Member]

2006 Equity Incentive Plan [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Minimum Threshold [Member]

Minimum Threshold [Member]

Minimum Threshold [Member]

Minimum Threshold [Member]

Target [Member]

Target [Member]

Target [Member]

Target [Member]

Maximum Goal [Member]

Maximum Goal [Member]

Maximum Goal [Member]

Maximum Goal [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2013 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2013 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2013 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2013 [Member]

Long Term Incentive Plan 2010 [Member]

Long Term Incentive Plan 2011 [Member]

Long Term Incentive Plan 2012 [Member]

Long Term Incentive Plan 2013 [Member]

Chief Financial Officer [Member]

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Board of Directors has the authority to issue preferred stock (in shares)

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of stock-based employee compensation plans

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of options, RSAs, and RSUs, minimum (in years)

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of options, RSAs, and RSUs, maximum (in years)

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date after grant date, minimum (in years)

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date after date of grant, maximum (in years)

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum percentage of contribution to ESPP

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount Rate of Common Stock for ESPP

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized for future issuance (in shares)

4,275,753

4,827,116

'

393,478

3,882,275

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares eligable for purchase

'

'

'

393,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Actual maximum number of RSU shares granted (in shares)

'

'

'

'

'

'

'

'

'

49,848

'

44,740

'

24,608

17,931

'

132,930

'

119,304

'

98,434

71,727

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weight of trading price of Luminex Common Stock in performance goals (in hundredths)

'

'

'

'

'

50.00%

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weight of Luminex's total income from operations per diluted share in performance goals (in hundredths)

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weight of Luminex's operating cash flows per diluted share in performance goals (in hundredths)

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weight of Luminex's total income from operations in performance goals (in hundredths)

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trading price targets (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$22.22

$28.50

$29.29

'

$25.25

$32.38

$32.54

'

$40.09

$51.42

$39.75

'

'

'

Earned (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,063

18,835

Income from operations targets (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.73

'

$1.06

'

$0.81

'

$1.18

'

$1.19

'

$1.36

'

'

Value of unvested RSUs granted

'

'

'

'

'

'

'

'

$825,000

'

$825,000

'

$550,000

'

$300,000

$2,200,000

'

$2,200,000

'

$2,200,000

'

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating cash flow targets (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.21

'

'

'

$0.24

'

'

'

$0.38

'

'

'

'

'

Income From Operations Targets (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$58,663,000

'

'

'

$67,286,000

'

'

'

$85,831,000

'

'

'

STOCKHOLDERS_EQUITY_EMPLOYEE_B3

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$0	$0	$0	'
Fair value assumptions used [Abstract]	'	'	'	'
Dividend yield (in hundredths)	0.00%	0.00%	0.00%	'
Expected volatility (in hundredths)	50.00%	50.00%	50.00%	'
Risk-free rate of return (in hundredths)	1.20%	1.20%	2.30%	'
Expected life	'7 years	'7 years	'7 years	'
Weighted average fair value at grant date (in dollars per share)	$8.79	$7.78	$7.67	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Total intrinsic value of stock options exercised	8,700,000	6,900,000	2,900,000	'
Total fair value of stock options vested	2,500,000	2,000,000	1,900,000	'
Unrecognized compensation costs, weighted-average period of recognition	'1 year 8 months 12 days	'	'	'
Percentage of employer matching contribution (in hundredths)	50.00%	50.00%	50.00%	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Stock options, outstanding [Roll Forward]	'	'	'	'
Vested and expected to vest, end of period (in shares)	578,000	'	'	'
Exercisable, ending balance (in shares)	40,000	'	'	'
Weighted-average remaining contractual life, outstanding, end of period	'1 year 9 months 26 days	'	'	'
Weighted-average remaining contractual life, vested and expected to vest, end of period	'1 year 9 months 22 days	'	'	'
Weighted-average remaining contractual life, exercisable, end of period	'0 days	'	'	'
Aggregate intrinsic value, outstanding, end of period	16,167,000	'	'	'
Aggregate intrinsic value, vested and expected to vest, end of period	10,439,000	'	'	'
Aggregate intrinsic value, exercisable, end of period	766,000	'	'	'
Equity instruments other than options, nonvested [Roll Forward]	'	'	'	'
Non-vested, beginning of period (in shares)	875,000	827,000	768,000	'
Granted (in shares)	199,051	246,205	268,882	'
Vested (in shares)	-79,000	-80,000	-58,000	'
Cancelled or expired (in shares)	-162,000	-118,000	-152,000	'
Non-vested, end of period (in shares)	833,000	875,000	827,000	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Grant-date fair value, minimum (in dollars per share)	$16.73	$16.16	$18.26	'
Grant-date fair value, maximum (in dollars per share)	$20.51	$23.82	$20.92	'
Restricted Shares [Member]	'	'	'	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Total unrecognized compensation costs	17,100,000	'	'	'
Unrecognized compensation costs, weighted-average period of recognition	'2 years 7 months 6 days	'	'	'
Total fair value of restricted shares vested	7,200,000	8,300,000	7,300,000	'
Compensation costs charged to expense	7,500,000	8,400,000	10,200,000	'
Restricted Stock [Member]	'	'	'	'
Fair value assumptions used [Abstract]	'	'	'	'
Weighted average fair value at grant date (in dollars per share)	$18.62	$19.32	$17.13	$16.41
Equity instruments other than options, nonvested [Roll Forward]	'	'	'	'
Non-vested, beginning of period (in shares)	818,000	903,000	1,093,000	'
Granted (in shares)	353,537	329,096	238,812	'
Vested (in shares)	-267,000	-339,000	-362,000	'
Cancelled or expired (in shares)	-79,000	-75,000	-67,000	'
Non-vested, end of period (in shares)	826,000	818,000	903,000	'
Granted, weighted-average grant-date fair value (in dollars per share)	$17.28	$22.50	$18.73	'
Vested, weighted-average grant-date fair value (in dollars per share)	$18.83	$16.75	$16.11	'
Cancelled or expired, weighted-average grant-date fair value (in dollars per share)	$19.15	$18.59	$16.57	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Grant-date fair value, minimum (in dollars per share)	$16.18	$17.26	$18.26	'
Grant-date fair value, maximum (in dollars per share)	$18.11	$22.71	$21	'
Stock Options [Member]	'	'	'	'
Stock options, outstanding [Roll Forward]	'	'	'	'
Options outstanding, beginning of period (in shares)	1,676,000	2,020,000	2,367,000	'
Granted (in shares)	159,000	160,000	84,000	'
Exercised (in shares)	-835,000	-487,000	-304,000	'
Cancelled or expired (in shares)	-33,000	-17,000	-127,000	'
Options outstanding, end of period (in shares)	967,000	1,676,000	2,020,000	'
Vested and expected to vest, end of period (in shares)	965,000	'	'	'
Exercisable, ending balance (in shares)	701,000	'	'	'
Weighted-average exercise price, end of period (in dollars per share)	$15.35	$12.13	$10.19	$10.82
Weighted-average exercise price, granted (in dollars per share)	$17.24	$22.53	$18.26	'
Weighted average exercise price, exercised (in dollars per share)	$9.06	$7.22	$11.65	'
Weighted-average exercise price, cancelled or expired (in dollars per share)	$19.80	$20.37	$23.74	'
Weighted-average exercise price, vested and expected to vest, end of period (in dollars per share)	$15.34	'	'	'
Weighted-average exercise price, exercisable, end of period (in dollars per share)	$13.91	'	'	'
Weighted-average remaining contractual life, outstanding, end of period	'4 years 7 months 24 days	'	'	'
Weighted-average remaining contractual life, vested and expected to vest, end of period	'4 years 7 months 21 days	'	'	'
Weighted-average remaining contractual life, exercisable, end of period	'3 years 1 month 21 days	'	'	'
Aggregate intrinsic value, outstanding, end of period	4,417,000	'	'	'
Aggregate intrinsic value, vested and expected to vest, end of period	4,413,000	'	'	'
Aggregate intrinsic value, exercisable, end of period	4,066,000	'	'	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Total unrecognized compensation costs	1,900,000	'	'	'
Proceeds from exercise of stock options	7,600,000	3,500,000	3,500,000	'
Employee Stock [Member]	'	'	'	'
Fair value assumptions used [Abstract]	'	'	'	'
Dividend yield (in hundredths)	0.00%	'	'	'
Expected volatility (in hundredths)	51.00%	'	'	'
Expected life	'6 months	'	'	'
Stock options, additional disclosures [Abstract]	'	'	'	'
Compensation costs charged to expense	$400,000	$200,000	'	'
Minimum [Member] | Employee Stock [Member]	'	'	'	'
Fair value assumptions used [Abstract]	'	'	'	'
Risk-free rate of return (in hundredths)	0.09%	'	'	'
Maximum [Member] | Employee Stock [Member]	'	'	'	'
Fair value assumptions used [Abstract]	'	'	'	'
Risk-free rate of return (in hundredths)	0.15%	'	'	'

STOCKHOLDERS_EQUITY_EMPLOYEE_B4

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Maximum individual contribution to 401(k) plan per year	$17,500	$17,000	$16,500
Percentage of employer matching contribution (in hundredths)	50.00%	50.00%	50.00%
Employer's contributions to 401(k) and deferred profit sharing plan	2,400,000	2,100,000	1,600,000
Fair value assumptions used [Abstract]	'	'	'
Risk-free rate of return (in hundredths)	1.20%	1.20%	2.30%
Expected life	'7 years	'7 years	'7 years
Expected volatility (in hundredths)	50.00%	50.00%	50.00%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Cost of Sales [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	856,000	947,000	917,000
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	2,553,000	2,034,000	2,126,000
General and Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	5,812,000	6,934,000	8,374,000
Reflected in Net Income (Loss) [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	9,221,000	9,915,000	11,417,000
Employee Stock [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation costs	$400,000	$200,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000	'	'
Number of shares eligable for purchase	393,000	'	'
Percentage Of Purchase Price Of Common Stock Under ESPP	85.00%	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	106,522	35,296	'
Fair value assumptions used [Abstract]	'	'	'
Expected life	'6 months	'	'
Expected volatility (in hundredths)	51.00%	'	'
Dividend yield (in hundredths)	0.00%	'	'
Minimum [Member] | Employee Stock [Member]	'	'	'
Fair value assumptions used [Abstract]	'	'	'
Risk-free rate of return (in hundredths)	0.09%	'	'
Maximum [Member] | Employee Stock [Member]	'	'	'
Fair value assumptions used [Abstract]	'	'	'
Risk-free rate of return (in hundredths)	0.15%	'	'

STOCKHOLDERS_EQUITY_EMPLOYEE_B5

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 4)	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	2,039,936	'
Shares available for future issuance (in shares)	4,275,753	4,827,116
Total shares reserved (in shares)	6,315,689	'
Long-Term Incentive Plan 2000 Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	97,000	'
Shares available for future issuance (in shares)	0	'
Total shares reserved (in shares)	97,000	'
Broad-Based Stock Option Plan 2001 Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	27,060	'
Shares available for future issuance (in shares)	0	'
Total shares reserved (in shares)	27,060	'
2006 Equity Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	1,715,876	'
Shares available for future issuance (in shares)	3,882,275	'
Total shares reserved (in shares)	5,598,151	'
Employee Stock Purchase Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	0	'
Shares available for future issuance (in shares)	393,478	'
Total shares reserved (in shares)	393,478	'
Balthrop Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options/ warrants outstanding (in shares)	200,000	'
Shares available for future issuance (in shares)	0	'
Total shares reserved (in shares)	200,000	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Lease periods maximum (in years)	'	10	'	'
Rental and lease expense	'	$5,100,000	$5,500,000	$3,600,000
Operating leases future minimum payments due [Abstract]	'	'	'	'
2014	'	4,120,000	'	'
2015	'	2,785,000	'	'
2016	'	1,811,000	'	'
2017	'	1,498,000	'	'
2018	'	1,310,000	'	'
Thereafter	'	5,516,000	'	'
Total	'	17,040,000	'	'
Non-cancelable purchase commitments	'	12,100,000	'	'
Distribution Agreement Settlement	$7,000,000	'	'	'

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Intersegment sales	'	'	'	'	'	'	'	'	$10,700,000	$11,700,000	$8,800,000
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues from external customers	55,156,000	50,780,000	54,287,000	53,200,000	55,535,000	50,047,000	48,273,000	48,727,000	213,423,000	202,582,000	184,339,000
Depreciation and amortization	'	'	'	'	'	'	'	'	15,922,000	14,364,000	11,887,000
Segment operating profit (loss)	5,472,000	-4,194,000	5,041,000	-1,552,000	7,255,000	3,367,000	6,486,000	5,608,000	4,767,000	22,716,000	23,843,000
Segment assets	306,046,000	'	'	'	297,175,000	'	'	'	306,046,000	297,175,000	'
Technology and Strategic Partnerships [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues from external customers	'	'	'	'	'	'	'	'	132,023,000	121,032,000	'
Depreciation and amortization	'	'	'	'	'	'	'	'	7,990,000	6,930,000	'
Segment operating profit (loss)	'	'	'	'	'	'	'	'	33,761,000	27,829,000	'
Segment assets	154,174,000	'	'	'	140,896,000	'	'	'	154,174,000	140,896,000	'
Assays and Related Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues from external customers	'	'	'	'	'	'	'	'	81,400,000	81,550,000	'
Depreciation and amortization	'	'	'	'	'	'	'	'	7,932,000	7,434,000	'
Segment operating profit (loss)	'	'	'	'	'	'	'	'	-28,994,000	-5,113,000	'
Segment assets	151,872,000	'	'	'	156,279,000	'	'	'	151,872,000	156,279,000	'
Research and Development Expense [Member] | Assays and Related Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Prior Period Reclassification Adjustment	'	'	'	'	'	'	'	'	'	2,100,000	2,000,000
Selling, General and Administrative Expenses [Member] | Assays and Related Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Prior Period Reclassification Adjustment	'	'	'	'	'	'	'	'	'	$12,700,000	$12,400,000

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Details 2) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues from external customers

$55,156,000

$50,780,000

$54,287,000

$53,200,000

$55,535,000

$50,047,000

$48,273,000

$48,727,000

$213,423,000

$202,582,000

$184,339,000

Long-Term Assets

159,676,000

'

'

'

168,398,000

'

'

'

159,676,000

168,398,000

123,670,000

Aggregate foreign currency transaction losses

'

'

'

'

'

'

'

'

385,000

215,000

'

Domestic Country [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues from external customers

'

'

'

'

'

'

'

'

178,276,000

167,924,000

152,480,000

Long-Term Assets

109,448,000

'

'

'

113,700,000

'

'

'

109,448,000

113,700,000

66,094,000

Europe [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues from external customers

'

'

'

'

'

'

'

'

16,690,000

17,376,000

16,029,000

Long-Term Assets

1,012,000

'

'

'

1,433,000

'

'

'

1,012,000

1,433,000

978,000

Asia [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues from external customers

'

'

'

'

'

'

'

'

12,287,000

10,877,000

9,481,000

Long-Term Assets

234,000

'

'

'

212,000

'

'

'

234,000

212,000

280,000

Canada [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Purchase Price Allocation, Goodwill Amount

39,600,000

'

'

'

'

'

'

'

39,600,000

'

'

Revenues from external customers

'

'

'

'

'

'

'

'

3,025,000

3,753,000

2,892,000

Long-Term Assets

46,535,000

[1]

'

'

'

48,929,000

[1]

'

'

'

46,535,000

[1]

48,929,000

[1]

52,028,000

[1]

Australia [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Purchase Price Allocation, Goodwill Amount

2,300,000

'

'

'

2,700,000

'

'

'

2,300,000

2,700,000

'

Revenues from external customers

'

'

'

'

'

'

'

'

1,299,000

963,000

1,344,000

Long-Term Assets

2,443,000

[2]

'

'

'

4,108,000

[3]

'

'

'

2,443,000

[2]

4,108,000

[3]

4,252,000

[3]

Other Countries [Member]

'

'

'

'

'

'

'

'

'

'

'

Revenues from External Customers and Long-Lived Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues from external customers

'

'

'

'

'

'

'

'

1,846,000

1,689,000

2,113,000

Long-Term Assets

$4,000

'

'

'

$16,000

'

'

'

$4,000

$16,000

$38,000

[1]

[1] $39.6 million of the long-term assets in Canada represents goodwill from the acquisition of Tm Bioscience.

[2]

[2] $2.3 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.

[3]

[3] $2.7 million of the long-term assets in Australia represent goodwill from the acquisition of BSD.

SELECTED_QUARTERLY_RESULTS_Det

SELECTED QUARTERLY RESULTS (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$55,156	$50,780	$54,287	$53,200	$55,535	$50,047	$48,273	$48,727	$213,423	$202,582	$184,339
Gross Profit	36,831	30,781	38,057	37,957	39,357	35,045	34,412	33,760	143,626	142,574	125,490
Income from operations	5,472	-4,194	5,041	-1,552	7,255	3,367	6,486	5,608	4,767	22,716	23,843
Net income	$5,116	$796	$3,695	($2,511)	$4,252	$1,676	$2,952	$3,527	$7,096	$12,407	$14,474
Net income per share, basic (in dollars per share)	$0.12	$0.02	$0.09	($0.06)	$0.10	$0.04	$0.07	$0.09	$0.17	$0.30	$0.35
Net income per share, diluted (in dollars per share)	$0.12	$0.02	$0.09	($0.06)	$0.10	$0.04	$0.07	$0.08	$0.17	$0.30	$0.34